COVID-19 vaccine; SARS CoV-2 vaccine

From Aaushi
Jump to navigation Jump to search

Introduction

COVID-19 vaccine overview[55]

comparison of Pfizer, Moderna, Astra-Zeneca & Johnson&Johnson vaccines[70]

Indications

* Pfizer vaccine FDA-approved for emergency use authorization Dec 11, 2020[32][33]

* Moderna vaccine (Spikevax) FDA-approved for emergency use authorization Dec 18, 2020[38]

Contraindications

* migraine prevention, including monoclonal Ab targeting CGRP pathway or Botox is not a contraindication[74]

* Moderna & Pfizer mRNA vaccines safe during pregnancy & breastfeeding[133][199]

* safe & effective to administer Covid-19 vaccine & influenza vaccine at same time[262]

Dosage

Adverse effects

* Also see v-safe in Patient information

Drug interactions

Mechanism of action

Clinical trials

mRNA vaccine

Moderna's mRNA-1273 vaccine (Spikevax)

Pzifer & NioNTech BNT162b2 vaccine

CurVac/GalaxoSmithKline (CVnCoV) mRNA vaccine

About mRNA vaccine

* quiescent spike protein-specific bone marrow plasma cells recovered 8 months after COVID-19 infection suggesting long-lived immunity (see Covid-19 pathology section)

Adenovirus vaccine

Johnson & Johnson's Ad26.COV2.S vaccine

Oxford/AstraZeneca/AZD1222 adenovirus vaccine

Sputnik V adenovirus vaccine

  • Sputnik V a non-replicating adenovirus type-5 (Ad5) vectored vaccine expressing the spike glycoprotein safe & induces immune response in > 94-100% of humans[2]
    • rAd26 & rAd5 (Sputnik V) adenovirus vaccine shows 92% efficacy in interim results from a phase 3 trial[66]
    • safe & effective[185] ~70 nations, but does not have WHO approval

vaccine to vaccinate the world

inactivated SARS CoV-2 vaccine

protein subunit vaccine

DNA vaccines

Intranasal vaccine

Inhaled vaccine

  • plans to start a phase I/II trial of inhaled vaccine (China)[149]
  • an inhaled version of a COVID-19 vaccine, produced by the Chinese company CanSino Biologics in Tianjin, was approved for use as a booster dose in China.[288]

Oral vaccine

Vaccines in development

* a discussion of COVID-19 vaccines in development[50]

putative vaccines not effective

Breakthrough infections

Notes

More general terms

More specific terms

Additional terms

References

  1. Ellis R First COVID-19 Vaccine Tested on Humans Shows Early Promise, Medscape - May 18, 2020 https://www.medscape.com/viewarticle/930714
  2. 2.0 2.1 Zhu FC, Li YH, Guan XH et al Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020 May 22;S0140-6736(20)31208-3 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32450106 Free PMC article https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext
  3. 3.0 3.1 Baumgaertner E Injection may block virus, but feds have refused to act. Los Angeles Times. July 11, 2020
  4. 4.0 4.1 Jackson LA, Anderson EJ, Rouphael NG et al An mRNA Vaccine against SARS-CoV-2 - Preliminary Report N Engl J Med, July 14, 2020 PMID: https://www.ncbi.nlm.nih.gov/pubmed/3266391 https://www.nejm.org/doi/full/10.1056/NEJMoa2022483
  5. 5.0 5.1 Heaton PM The Covid-19 Vaccine-Development Multiverse. N Engl J Med, July 14, 2020 PMID: https://www.ncbi.nlm.nih.gov/pubmed/3266391 https://www.nejm.org/doi/full/10.1056/NEJMe2025111C
  6. 6.0 6.1 Folegatti PM, Ewer KJ, Aley PK et al Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. July 20, 2020 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32702298 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext
  7. Zhu FC, Guan XH, Li YH et al Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. July 20, 2020 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32450106 Free PMC article https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext
  8. 8.0 8.1 Corbett KS, Flynn B, Foulds KF et al Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. July 28, 2020 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32722908 https://www.nejm.org/doi/full/10.1056/NEJMoa2024671
  9. 9.0 9.1 9.2 Fiore K DIY COVID Vaccine; Small Company, Big Results; Health Worker Death to Be Probed. MedPage Today August 5, 2020 https://www.medpagetoday.com/infectiousdisease/covid19/87910
    Rigaldo A Some scientists are taking a DIY coronavirus vaccine, and nobody knows if it's s legal or if it works. MIT Technology Review. July 29, 20202 https://www.technologyreview.com/2020/07/29/1005720/george-church-diy-coronavirus-vaccine/
    Rapid Deployment Vaccine Collaborative (RADVAC) https://radvac.org/
  10. 10.0 10.1 Kramer AE Russia Approves Coronavirus Vaccine Before Completing Tests. New York Times. Aug. 11, 2020 https://www.nytimes.com/2020/08/11/world/europe/russia-coronavirus-vaccine-approval.html
  11. 11.0 11.1 Xia S, Duan K, Zhang Y et al Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes. Interim Analysis of 2 Randomized Clinical Trials. JAMA. Published online August 13, 2020 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32789505 https://jamanetwork.com/journals/jama/fullarticle/2769612
    Mulligan MJ An Inactivated Virus Candidate Vaccine to Prevent COVID-19. JAMA. Published online August 13, 2020 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32789500 https://jamanetwork.com/journals/jama/fullarticle/2769609
  12. 12.0 12.1 Schachar RA, Schachar, IH. A SARS-CoV-2 mRNA Vaccine. Preliminary Report. N Engl J Med. August 19, 2020 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32813940 https://www.nejm.org/doi/full/10.1056/NEJMc2026616
  13. 13.0 13.1 Walsh EE, Frenck R, Falsey AR et al RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study. medRxiv August 20, 2020 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32839784 PMCID: PMC7444302 Free PMC article https://www.medrxiv.org/content/10.1101/2020.08.17.20176651v1
  14. 14.0 14.1 moderna August 26, 20202 mRNA-1273 Vaccine Against COVID-19Phase 1 Interim Analysis of Older Adult Cohorts (ages 56-70 and 71+) https://investors.modernatx.com/static-files/1dc3deaf-4a1b-46f8-8aed-33bfd7b2c979
  15. 15.0 15.1 Keech C. Albert G, Cho I et al Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Eng J Med Sept 2, 2020 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32877576 https://www.nejm.org/doi/full/10.1056/NEJMoa2026920
  16. 16.0 16.1 McNamara D straZeneca Pauses COVID-19 Vaccine Trials Due to 'Unexplained Illness. Medscape - Sep 09, 2020. https://www.medscape.com/viewarticle/937101
    AstraZeneca Oxford Press Release Sept 9, 2020 Statement on AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary pause. https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/statement-on-astrazeneca-oxford-sars-cov-2-vaccine-azd1222-covid-19-vaccine-trials-temporary-pause.html
  17. 17.0 17.1 Sadoff J et al Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. medRxiv. Sept 25 2020 Not indexed in PubMed https://www.medrxiv.org/content/10.1101/2020.09.23.20199604v1
  18. Szabo L, Aleccia J Signs of an 'October Vaccine Surprise' Alarm Career Scientists Medscape - Sep 28, 2020. https://www.medscape.com/viewarticle/938188
  19. 19.0 19.1 19.2 19.3 Walsh EE et al Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med 2020. Oct 14 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33053279 https://www.nejm.org/doi/full/10.1056/NEJMoa2027906
  20. 20.0 20.1 Krause PR, Gruber MF. Perspective: Emergency Use Authorization of Covid Vaccines - Safety and Efficacy Follow-up Considerations. N Engl J Med. 2020. Oct 16. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33064383 https://www.nejm.org/doi/full/10.1056/NEJMp2031373
  21. 21.0 21.1 McNeil DG Jr A nasal spray prevented Covid-19 infection in ferrets, a study finds. New York Times. Nov 6, 2020 via MSN News https://www.msn.com/en-us/news/world/a-nasal-spray-prevented-covid-19-infection-in-ferrets-a-study-finds/ar-BB1aLJne
    de Vries RD, Schmitz KS, Bovier FT et al Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2transmissionin ferrets. bioRxiv preprint. Nov 5, 2020 https://www.biorxiv.org/content/10.1101/2020.11.04.361154v1.full.pdf
    de Vries RD, Schmitz KS, Bovier FT et al Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets. Science 2021. Feb 17 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33597220 https://science.sciencemag.org/content/early/2021/02/16/science.abf4896
  22. 22.0 22.1 22.2 22.3 22.4 Moderna. Nov 16, 2020 Moderna's COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy
    Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-longer-shelf-life-its-covid-19-vaccine
  23. 23.0 23.1 23.2 Pfizer news release. Nov 18, 2020 https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine
  24. 24.0 24.1 COVID-19 Oxford vaccine trial. Nov 2020 Oxford University breakthrough on global COVID-19 vaccine https://covid19vaccinetrial.co.uk/breakthrough-global-covid-19-vaccine
    AstraZeneca. Nov 23, 2020 AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19 https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/azd1222hlr.html
  25. McClung N, Chamberland M, Kinlaw K, et al. The Advisory Committee on Immunization Practices' Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020. MMWR Morb Mortal Wkly Rep. ePub: 23 November 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6947e3.htm
  26. 26.0 26.1 McNamara D Moderna Filing for FDA Emergency COVID Vaccine Approval, Reports 94.1% Efficacy. Medscape - Nov 30, 2020. https://www.medscape.com/viewarticle/941730
    Moderna Press Release. Nov 30, 2020 Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study
  27. 27.0 27.1 Widge AT et al Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N Eng J Med 2020. Dec 3 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33270381 https://www.nejm.org/doi/full/10.1056/NEJMc2032195
  28. 28.0 28.1 Vaccines and Related Biological Products. Advisory Committee MeetingDecember 10, 2020 FDA Briefing Document. Pfizer-BioNTech COVID-19 Vaccine https://www.fda.gov/media/144245/download
  29. 29.0 29.1 Ramasamy MN et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet 2020 Nov 18; PMID: https://www.ncbi.nlm.nih.gov/pubmed/33220855 Free PMC article https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext
    Voysey M et al Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020. Dec 8 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33306989 Free PMC article. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext
    Knoll MD, Wonodi C Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2020. Dec 8 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33306990 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32623-4/fulltext
  30. 30.0 30.1 Reuters UAE Says Sinopharm Vaccine Has 86% Efficacy Against COVID-19 Medscape - Dec 09, 2020. https://www.medscape.com/viewarticle/942310
  31. 31.0 31.1 Kirka D UK probes whether COVID-19 vaccine caused allergic reactions. Associated Press. Dec 9, 2020 https://apnews.com/article/uk-allergic-reaction-pfizer-vaccine-64ddccd70c38a39f880da27941db3540
  32. 32.0 32.1 32.2 32.3 Walker M FDA Panel: Thumbs Up for Pfizer/BioNTech COVID Vax - Main point of contention was age of participants in a largely lopsided vote. https://www.medpagetoday.com/infectiousdisease/covid19/90144
    Polack FP, Thomas SJ, Kitchin N et al ' Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Eng J Med 2020. Dec 10 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33301246 https://www.nejm.org/doi/full/10.1056/NEJMoa2034577
    Rubin EJ, Longo DL. SARS-CoV-2 Vaccination - An Ounce (Actually, Much Less) of Prevention. N Eng J Med 2020. Dec 10 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33301245 https://www.nejm.org/doi/full/10.1056/NEJMe2034717
    Vaccines and Related Biological Products. Advisory Committee Meeting. December 10, 2020FDA Briefing Document. Pfizer-BioNTech COVID-19 Vaccine. https://www.fda.gov/media/144245/download
  33. 33.0 33.1 McNamara D FDA OKs Emergency Use of Pfizer COVID-19 Vaccine. Medscape - Dec 11, 2020. https://www.medscape.com/viewarticle/942479
  34. Ault A CDC Panel Recommends Pfizer's COVID-19 Vaccine for People 16 and Over. Medscape - Dec 12, 2020 https://www.medscape.com/viewarticle/942558
  35. 35.0 35.1 Young KD Moderna COVID-19 Vaccine Gets Positive Review From FDA Staff. Medscape - Dec 15, 2020. https://www.medscape.com/viewarticle/942682
  36. 36.0 36.1 Crist C Few Cases of Facial Paralysis Seen After COVID Vaccine. Medscape - Dec 16, 2020 https://www.medscape.com/viewarticle/942759
  37. 37.0 37.1 Centers for Disease Control & Prevention (CDC). Dec 12, 2020 Interim Clinical Considerations for Use of Pfizer-BioNTech COVID-19 Vaccine. https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/clinical-considerations.html
    Centers for Disease Control & Prevention (CDC) Feb 10, 2021 Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States. https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html
    Centers for Disease Control & Prevention (CDC). Feb 11, 2021 When to Quarantine https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/quarantine.html
  38. 38.0 38.1 38.2 Grady D, Goodnough A, Zimmer D, Wu KJ. F.D.A. Panel Endorses Moderna's Coronavirus Vaccine. New York Times. 2020. Dec 17 https://www.msn.com/en-us/health/medical/fda-panel-endorses-modernas-coronavirus-vaccine/ar-BB1c1hFM
    FDA Briefing Document, Moderna COVID-19 Vaccine. December 17, 2020 Vaccines and Related Biological Products Advisory Committee Meeting https://www.fda.gov/media/144434/download
    McNamara D FDA Grants Emergency Use for Moderna COVID-19 Vaccine Medscape - Dec 18, 2020 https://www.medscape.com/viewarticle/942920
    Grady D, Goodnough A, Weiland N F.D.A. Clears Moderna's Covid Vaccine New York Times. Dec 18, 2020 https://www.msn.com/en-us/news/us/fda-clears-modernas-covid-vaccine/ar-BB1c3sdj
    Hanna J, Waldrop T, Maxouris C. FDA authorizes a second vaccine as average daily cases and deaths hit records. CNN Health. 2020. Dec 18 https://www.cnn.com/2020/12/18/health/us-coronavirus-friday/index.html
  39. 39.0 39.1 Levenson E, Howard J What we know about Moderna's coronavirus vaccine and how it differs from Pfizer's. CNN Health. 2020, Dec 17 https://www.cnn.com/2020/12/17/health/moderna-vaccine-what-we-know/index.html
  40. 40.0 40.1 Thomas K Hospitals Discover a Surprise in Their Vaccine Deliveries: Extra Doses. New York Times, Dec 16, updated Dec 17 2020 https://www.nytimes.com/2020/12/16/health/Covid-Pfizer-vaccine-extra-doses.html
  41. 41.0 41.1 41.2 41.3 Anderson EJ, Rouphael NG, Widge AT et al Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med 2020; 383:2427-2438. Dec 17 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32991794 Free PMC article. https://www.nejm.org/doi/full/10.1056/NEJMoa2028436
  42. AMA Morning Rounds. Dec 21,2020 American Medical Association
  43. 43.0 43.1 43.2 43.3 43.4 Branswell H A side-by-side comparison of the Pfizer/BioNTech and Moderna vaccines. STAT Health. 2020. Dec 19 https://www.statnews.com/2020/12/19/a-side-by-side-comparison-of-the-pfizer-biontech-and-moderna-vaccines/
    Haynes BF A New Vaccine to Battle Covid-19. N Eng J Med 2020. Dec 30 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33378607 https://www.nejm.org/doi/full/10.1056/NEJMe2035557
  44. 44.0 44.1 44.2 de Vrieze J Suspicions grow that nanoparticles in Pfizer's COVID-19 vaccine trigger rare allergic reactions. Science 2020. Dec 21. https://www.sciencemag.org/news/2020/12/suspicions-grow-nanoparticles-pfizer-s-covid-19-vaccine-trigger-rare-allergic-reactions
  45. 45.0 45.1 45.2 Baden LR, El Sahly HM, Essink B et al Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2020. Dec 30 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33378609 https://www.nejm.org/doi/full/10.1056/NEJMoa2035389
  46. Castells MC, Phillips EJ Maintaining Safety with SARS-CoV-2 Vaccines. N Engl J Med 2020. Dec 30 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33378605 https://www.nejm.org/doi/full/10.1056/NEJMra2035343
  47. Cennimo DJ, Bergman SJ COVID-19 Vaccines. Medscape. Dec 31, 2020 https://emedicine.medscape.com/article/2500139-overview
  48. 48.0 48.1 48.2 National Institutes of Health. Press Release. Dec 28, 2020 Phase 3 trial of Novavax investigational COVID-19 vaccine opens https://www.nih.gov/news-events/news-releases/phase-3-trial-novavax-investigational-covid-19-vaccine-opens
    Walker M Good News, Bad News for Novavax COVID Vaccine - Encouraging British data; but results from South Africa bring more questions than answers. MedPage Today January 28, 2021 https://www.medpagetoday.com/infectiousdisease/covid19/90940
    Novavax Press Release, Jan 28, 2021 Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial. https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3
  49. 49.0 49.1 CDC COVID-19 Response Team; Food & Drug Administration Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - nited States, December 14-23 2020. MMWR Morb Mortal Wkly Rep. ePub: 6 January 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33444297 https://www.cdc.gov/mmwr/volumes/70/wr/mm7002e1.htm
  50. 50.0 50.1 Gardner J, Pagliarulo N, Fidler B The first coronavirus vaccines have arrived. Here's where the rest stand. BioPharma Dive Jan 7, 2021 https://www.biopharmadive.com/news/coronavirus-vaccine-pipeline-types/579122/
  51. 51.0 51.1 Xie X, Zou J, Fontes-Garfias CR et al Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. bioRxiv, Jan 7, 2021 https://www.biorxiv.org/content/10.1101/2021.01.07.425740v1
  52. 52.0 52.1 AMA Morning News. Jan 12, 2021 American Medical Association
    Ellerbeck A The Health 202: Recovered coronavirus patients should still get the vaccine, experts say. Washington Post. Jan 11, 2021 https://www.washingtonpost.com/politics/2021/01/11/health-202-recovered-coronavirus-patients-should-still-get-vaccine-experts-say/
  53. 53.0 53.1 53.2 Sadoff J, Le Gars M, Shukarev G et al Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med 2021. Jan 13. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33440088 https://www.nejm.org/doi/full/10.1056/NEJMoa2034201
  54. 54.0 54.1 Muik A, Wallisch AK, Sanger B et al Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. bioRxiv 2021 Jan 19 Not indexed in PubMed https://www.biorxiv.org/content/10.1101/2021.01.18.426984v1.full.pdf
  55. 55.0 55.1 Cennimo DJ et al COVID-19 Vaccines: Vaccines in Late-Stage Development. Medscape. Jan 14, 2021 https://emedicine.medscape.com/article/2500139-overview
  56. 56.0 56.1 Shimabukuro T, Nair N. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine. JAMA. Published online January 21, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33475702 https://jamanetwork.com/journals/jama/fullarticle/2775646
    Shimabukuro TT, Cole M, Su JR Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US - December 14, 2020-January 18, 2021. JAMA. 2021, Feb 12 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33576785 https://jamanetwork.com/journals/jama/fullarticle/2776557
  57. 57.0 57.1 Ellis R CDC: Gap Between Vaccine Doses Could Be 6 Weeks. Medscape - Jan 22, 2021 https://www.medscape.com/viewarticle/944569
  58. 58.0 58.1 Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020 - January 10, 2021. MMWR Morb Mortal Wkly Rep. ePub: 22 January 2021 https://www.cdc.gov/mmwr/volumes/70/wr/mm7004e1.htm
  59. 59.0 59.1 59.2 Wu K, Werner AP, Moliva JI et al mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv. 2021. Jan 25 Not indexed in PubMed https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1
    Wu K, Werner AP, Koch M et al Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine - Preliminary Report N Engl J Med 2021. Feb 17 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33596346 https://www.nejm.org/doi/full/10.1056/NEJMc2102179
  60. 60.0 60.1 60.2 60.3 World Health Organization (WHO) Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19. WHO Interim Guidance. Jan 25, 2021 https://apps.who.int/iris/bitstream/handle/10665/338862/WHO-2019-nCoV-vaccines-SAGE_recommendation-mRNA-1273-2021.1-eng.pdf
  61. 61.0 61.1 61.2 61.3 Moore JP, Offit PA SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants. JAMA. Published online January 28, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33507218 https://jamanetwork.com/journals/jama/fullarticle/2776039
  62. 62.0 62.1 62.2 Walker M J&J COVID-19 Vax Effective Against Severe Disease - But overall efficacy falls well short of competitors. MedPage Today January 29, 2021 https://www.medpagetoday.com/infectiousdisease/covid19/90942
    Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial. Johnson & Johnson. NEW BRUNSWICK, N.J., January 29, 2021 https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial
  63. 63.0 63.1 D'Ambrosio A Officials Investigate Physician's Death After COVID Vaccination - Onset of rare blood disorder should not be interpreted as causal, experts say. MedPage Today January 27, 2021 https://www.medpagetoday.com/special-reports/exclusives/90917
  64. 64.0 64.1 64.2 Oxford University, Feb 2, 2021 Oxford coronavirus vaccine shows sustained protection of 76% during the 3-month interval until the second dose. https://www.ox.ac.uk/news/2021-02-02-oxford-coronavirus-vaccine-shows-sustained-protection-76-during-3-month-interval
  65. 65.0 65.1 AMA Morning News. Feb 2, 2021 More Americans have received COVID-19 vaccine than have tested positive for virus, data indicate. American Medical Association
  66. 66.0 66.1 Logunov DY, Dolzhikova IV, Zubkova OV, et al Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020 Sep 26;396(10255):887-897. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32896291 Free PMC article
    Logunov DY, Dolzhikova IV, Shcheblyakov DV et al Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021. Feb 2 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33545094 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext
  67. 67.0 67.1 67.2 67.3 67.4 AstraZeneca News Release. Feb 3, 2021 COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials. https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-confirms-protection-against-severe-disease-hospitalisation-and-death-in-the-primary-analysis-of-phase-iii-trials.html
    Voysey M, Clemens SAC et al Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine. Preprints in the Lancet. Feb 1, 2021 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3777268
  68. 68.0 68.1 Mueller B, Robbins R, Chutel L South Africa says AstraZeneca's vaccine does't work well against a variant. New York Times. Feb 8, 2021 https://www.nytimes.com/live/2021/02/07/world/covid-19-coronavirus#south-africa-astrazeneca-vaccine
  69. 69.0 69.1 Edmonds CE, Zuckerman SP, Conant EF Management of Unilateral Axillary Lymphadenopathy Detected on Breast MRI in the Era of Coronavirus Disease (COVID-19) Vaccination. AJR 2021 Feb 5 [published online]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33543649 https://www.ajronline.org/doi/pdf/10.2214/AJR.21.25604
    Nelson R Armpit Swelling After COVID-19 Vaccine May Mimic Breast Cancer Medscape - Feb 25, 2021. https://www.medscape.com/viewarticle/946448
  70. 70.0 70.1 70.2 WebMD News Staff Four COVID Vaccines Compared. Medscape. Feb 5, 2021 https://www.medscape.com/viewarticle/945401
  71. McNamara D J&J Vaccine 85% Efficacious Against Severe COVID Globally. Medscape - Jan 29, 2021. https://www.medscape.com/viewarticle/944933
    Crist C Moderna Study: Vaccine Effective vs COVID Variants Medscape - Jan 25, 2021. https://www.medscape.com/viewarticle/944638
    Ellis R COVID Vaccine Effectiveness Falls Against South African Variant. Medscape - Jan 29, 2021. https://www.medscape.com/viewarticle/944964
    Pfizer. "IN VITRO STUDIES DEMONSTRATE PFIZER AND BIONTECH COVID-19 VACCINE ELICITS ANTIBODIES THAT NEUTRALIZE SARS-COV-2 WITH KEY MUTATIONS PRESENT IN U.K. AND SOUTH AFRICAN VARIANTS" https://www.pfizer.com/news/press-release/press-release-detail/vitro-studies-demonstrate-pfizer-and-biontech-covid-19
    Novavax. "Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial" https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3
  72. 72.0 72.1 World Health Organization (WHO) AZD1222 vaccine against COVID-19 developed by Oxford University and Astra Zeneca: Background paper (draft). COVID-19: Critical preparedness, readiness and response. Feb 10, 2021 https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-background-2021.1
    World Health Organization (WHO) WHO lists two additional COVID-19 vaccines for emergency use and COVAX roll-out. AstraZeneca/Oxford-developed vaccines to reach countries in the coming weeks. WHO News Release. Feb 15, 2021 https://www.who.int/news/item/15-02-2021-who-lists-two-additional-covid-19-vaccines-for-emergency-use-and-covax-roll-out
  73. 73.0 73.1 Fiore K Second COVID Shot Packs the Big Punch - First dose also worse for those with previous COVID, but "small price to pay" for protection. MedPage Today February 11, 2021 https://www.medpagetoday.com/special-reports/exclusives/91157
  74. 74.0 74.1 George J COVID Vaccine for Migraine Patients? - Headache, vaccine experts field questions from Twitter. MedPage Today February 12, 2021 https://www.medpagetoday.com/neurology/migraines/91193
    Gelfand AA, Poland G Migraine treatment and COVID-19 vaccines: no cause for concern. Headache. 2021. Feb 5 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33543775 https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.14086
  75. 75.0 75.1 75.2 Richmond P, Hatchuel L, Dong M et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: A phase 1, randomised, double-blind, placebo-controlled trial. Lancet 2021 Jan 29; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33524311 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00241-5/fulltext
  76. 76.0 76.1 76.2 Liu Y, Liu J, Xia H et al Neutralizing Activity of BNT162b2-Elicited Serum - Preliminary Report N Engl J Med. 2021. Feb 17 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33596352 https://www.nejm.org/doi/full/10.1056/NEJMc2102017
    Skowronski DM, De Serres G Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2021. Feb 17 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33596348. https://www.nejm.org/doi/pdf/10.1056/NEJMc2036242
  77. 77.0 77.1 77.2 77.3 McNamara D New Data Boost Calls for Single COVID-19 Vaccine Dose Medscape - Feb 18, 2021. https://www.medscape.com/viewarticle/946102
    Pancevski B, Lieber D Pfizer Vaccine is Highly Effective After One Dose and Can Be Stored in Normal Freezers, Data Shows. World. Feb 19, 2021 https://www.wsj.com/articles/single-dose-of-pfizer-vaccine-is-85-effective-israeli-study-shows-11613723218
    Ault A Pfizer Asks FDA to Approve Storage of COVID Vaccine in Standard Freezers. Medscape - Feb 19, 2021. https://www.medscape.com/viewarticle/946133
    FDA News Release. Feb 25, 2021 Coronavirus (COVID-19) Update: FDA Allows More Flexible Storage, Transportation Conditions for Pfizer-BioNTech COVID-19 Vaccine. Update Provides Alternative Temperature for Transportation and Temporary Storage for Frozen Vials Before Dilution/ https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-allows-more-flexible-storage-transportation-conditions-pfizer
    Reuters Staff Real-World' UK Data Show 70% Decline in COVID Infections After First Pfizer Shot Medscape - Feb 22, 2021. https://www.medscape.com/viewarticle/946208
  78. 78.0 78.1 Erman M Pfizer plans to test COVID-19 vaccine booster targeting the South African variant. Reuters. Feb 18, 2021 https://www.reuters.com/article/health-coronavirus-pfizer-variant/update-1-pfizer-plans-to-test-covid-19-vaccine-booster-targeting-the-south-african-variant-idUSL1N2KO28S
  79. 79.0 79.1 79.2 79.3 Kalter L https://www.medscape.com/viewarticle/945989
    Marks M, Millat-Martinez P, Ouchi D et al Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. Lancet Infect Dis. 2021 Feb 2:S1473-3099(20)30985-3 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33545090
    Pettet E. Mor O, Zuckerman N et al Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2. medRxiv. Feb 8, 2021 https://www.medrxiv.org/content/10.1101/2021.02.08.21251329v1
    Lopez Bernal J, Andrew N, Gower C et al Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. medRxiv 2021. March 2 Not indexed in PubMed https://khub.net/documents/135939561/430986542/Early+effectiveness+of+COVID+vaccines.pdf/ffd7161c-b255-8e88-c2dc-88979fc2cc1b
  80. 80.0 80.1 Gee J, Marquez P, Su J, et al. First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep. ePub: 19 February 2021. https://www.cdc.gov/mmwr/volumes/70/wr/mm7008e3.htm
  81. 81.0 81.1 Mandavilli A People Who Have Had Covid Should Get Single Vaccine Dose, Studies Suggest. New York Times. Feb 19, 2021 https://www.nytimes.com/2021/02/19/health/covid-vaccine-single-dose.html
    Samanovic MI, Cornelius AR, Wilson JP et al Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals. medRxiv. Feb 9, 2021 Not indexed in PubMed https://www.medrxiv.org/content/10.1101/2021.02.07.21251311v1
  82. 82.0 82.1 Stamatatos L, Czartoski J, Wan YH et al Antibodies elicited by SARS-CoV-2 infection and boosted by vaccination neutralize an emerging variant and SARS-CoV-1. medRxiv. Feb 8, 2021 Not indexed in PubMed https://www.medrxiv.org/content/10.1101/2021.02.05.21251182v1
  83. 83.0 83.1 Pailliez C, Ahlander J AstraZeneca Vaccine Faces Resistance in Europe After Health Workers Suffer Side Effects. Medscape - Feb 18, 2021. https://www.medscape.com/viewarticle/946050
  84. 84.0 84.1 84.2 84.3 luball M Israeli Studies Find Pfizer COVID-19 Vaccine Likely Reduces Transmission. Medscape - Feb 19, 2021. https://www.medscape.com/viewarticle/946121
  85. 85.0 85.1 McNamara D Janssen/J&J COVID-19 Vaccine Cuts Transmission, New Data Show. Medscape - Feb 24, 2021. https://www.medscape.com/viewarticle/946401
  86. Covid-19 Vaccine Resource Center New England Journal of Medicine Fauci: Data 'Favorable' That Vaccines Limit Transmission. Medscape - Feb 17, 2021. https://www.nejm.org/covid-vaccine
  87. 87.0 87.1 Vaccines and Related Biological Products Advisory Committee Meeting February 26, 2021 FDA Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19 https://www.fda.gov/media/146217/download
  88. Dagan N, Barda N, Kepten E et al BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021. Feb 24 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33626250 https://www.nejm.org/doi/full/10.1056/NEJMoa2101765
  89. 89.0 89.1 Creech CB, Walker SC, Samuels RJ SARS-CoV-2 Vaccines JAMA. Published online February 26, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33635317 https://jamanetwork.com/journals/jama/fullarticle/2777059
  90. Walker M J&J COVID Vaccine Gets Green Light from FDA Panel - No dissent on question of whether benefits outweigh risks. MedPage Today February 26, 2021 https://www.medpagetoday.com/infectiousdisease/covid19/91396
    Young KD J&J COVID-19 Vaccine Wins Unanimous Backing of FDA Panel. Medscape - Feb 26, 2021. https://www.medscape.com/viewarticle/946591
    Weiland N, LaFraniere S F.D.A. Clears Johnson & Johnson's Shot, the Third Vaccine for U.S. New York Times. Feb 27, 2021 https://www.nytimes.com/2021/02/27/health/covid-vaccine-johnson-and-johnson.html
    FDA News Release. Feb 27,2021 FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine
    Centers for Disease Control & Prevention (CDC) Media Statement from CDC Director Rochelle P. Walensky, MD, MPH, on Signing the Advisory Committee on Immunization Practices' Recommendation to Use Janssen's COVID-19 Vaccine in People 18 and Older. Media Statement. Feb 29, 2021. https://www.cdc.gov/media/releases/2021/s0228-JJ-vaccine.html
    Oliver SE, Gargano JW, Scobie H, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine - United States, February 2021. MMWR Morb Mortal Wkly Rep. ePub: 2 March 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33661860 https://www.cdc.gov/mmwr/volumes/70/wr/mm7009e4.htm
  91. 91.0 91.1 91.2 Worcester S COVID-19 Vaccination in Patients With Cancer: NCCN Outlines Priorities. Medscape - Feb 02, 2021. https://www.medscape.com/viewarticle/945100
  92. Blumenthal KG, Freeman EE, Saff RR et al Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2. N Engl J Med. 2021 March 3 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33657292 https://www.nejm.org/doi/full/10.1056/NEJMc2102131
  93. 93.0 93.1 93.2 93.3 93.4 Centers for Disease Control & Prevention (CDC) Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. Summary of recent changes (last updated March 3, 2021) https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html
  94. 94.0 94.1 Tucker ME BMI, Age, and Gender Affect COVID-19 Vaccine Antibody Response Medscape - Mar 03, 2021. https://www.medscape.com/viewarticle/946765
  95. 95.0 95.1 AMA Morning Rounds. March 9. 2021 American Medical Association
    Centers for Disease Control & Prevention (CDC) Science Brief: Background Rationale and Evidence for Public Health Recommendations for Fully Vaccinated People. Update March 8, 2021 https://www.cdc.gov/coronavirus/2019-ncov/more/fully-vaccinated-people.html
  96. 96.0 96.1 Krammer F, Srivastava K, Alshammary H et al Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. 2021. March 10 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33691060 https://www.nejm.org/doi/full/10.1056/NEJMc2101667
  97. 97.0 97.1 Stephenson KE, Le Gars M, Sadoff J et al Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA. Published online March 11, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33704352 https://jamanetwork.com/journals/jama/fullarticle/2777598
  98. 98.0 98.1 98.2 Erman M, Lubell M Pfizer/BioNTech Say Data Suggests Vaccine 94% Effective in Preventing Asymptomatic Infection Medscape - Mar 11, 2021. https://www.medscape.com/viewarticle/947289
  99. 99.0 99.1 Bosely S Netherlands joins Ireland in vaccine suspension over blood clot concerns. Suspension follows similar move in Ireland due to reports in Norway of blood clots despite no proof of a link. The Guardian. Sun 14 Mar 2021 19.38 https://www.theguardian.com/world/2021/mar/14/ireland-suspends-oxford-astrazeneca-covid-vaccine-over-blood-clot-concerns
    European Medicines Agency. Science Medicines Health COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events
    vaccine's benefits currently still outweigh risks - Update Share. News 11/03/2021
  100. 100.0 100.1 World Health Organization. March 17, 2021 Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine: interim guidance, 17 March 2021. https://apps.who.int/iris/handle/10665/340203
  101. 101.0 101.1 World Health Organization. March 17, 2021 WHO statement on AstraZeneca COVID-19 vaccine safety signals. https://www.who.int/news/item/17-03-2021-who-statement-on-astrazeneca-covid-19-vaccine-safety-signals
    European Medicines Agency COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets. News Release. March 18, 2021 https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots
  102. 102.0 102.1 Madhi SA, Baillie V, Cutland CL et al Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med 2021. March 16 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33725432 https://www.nejm.org/doi/full/10.1056/NEJMoa2102214
  103. 103.0 103.1 103.2 103.3 103.4 Reuters Staff Multiple Variants Can 'Escape' Vaccines Medscape - Mar 17, 2021 https://www.medscape.com/viewarticle/947660
    Garcia-Beltran WF, Lam EC, St. Denis K et al Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 2021. March 12 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33412089 PMCID: PMC7837114 Free PMC article https://www.cell.com/cell/fulltext/S0092-8674(21)00298-1
  104. 104.0 104.1 104.2 104.3 104.4 Boyarsky BJ, Werbel WA, Avery RK et al Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. JAMA. Published online March 15, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33720292 https://jamanetwork.com/journals/jama/fullarticle/2777685
    Boyarsky BJ, Werbel WA, Avery RK et al Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. Published online May 5, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33950155 https://jamanetwork.com/journals/jama/fullarticle/2779852
  105. 105.0 105.1 Reuters Staff No SARS-CoV-2 Variants Escape All Types of Antibodies, So Far Medscape - Mar 19, 2021 https://www.medscape.com/viewarticle/947816
    Greaney AJ, Starr TN, Barnes CO et al Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies. bioRxiv. 2021. March 18. Not indexed in PubMed https://www.biorxiv.org/content/10.1101/2021.03.17.435863v1
  106. 106.0 106.1 AstraZeneca AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis. News Release. March 22, 2021 https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/astrazeneca-us-vaccine-trial-met-primary-endpoint.html
  107. 107.0 107.1 McNamara D NIH Rebukes AstraZeneca Vaccine Interim Data: 'Incomplete' Medscape - Mar 23, 2021. https://www.medscape.com/viewarticle/947954
  108. 108.0 108.1 Keehner J, Horton LE, Pfeffer MA et al SARS-CoV-2 Infection after Vaccination in Health Care Workers in California. N Engl J Med. 2021. March 23 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33755376 https://www.nejm.org/doi/full/10.1056/NEJMc2101927
    Daniel W, Nivet M, Podolsky DK et al Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center. N Engl J Med. 2021. March 23 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33755374 https://www.nejm.org/doi/full/10.1056/NEJMc2102153
    Benenson S, Oster Y, Cohen MJ et al BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers. N Engl J Med. 2021. March 23 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33755373 https://www.nejm.org/doi/full/10.1056/NEJMc2101951
  109. 109.0 109.1 Ellis R Clinical Trials Planned for Oral COVID Vaccine. Medscape - Mar 24, 2021. https://www.medscape.com/viewarticle/948034
  110. 110.0 110.1 Lou N Hypertension After COVID Vax No Cause for Worry, So Far. Disagreement over special precautions for individuals with high BP. MedPage Today March 25, 2021 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/91814
    Meylan S, Livio F, Foerster M et al Stage III hypertension in patients after mRNA-based SARS-CoV-2 vaccination. Hypertension 2021. March 25 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33764160 ' https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.121.17316
  111. 111.0 111.1 Fiore K How Do COVID-19 Vaccines Compare? A side-by-side look at the three vaccines authorized in the U.S. MedPage Today March 5, 2021 https://www.medpagetoday.com/special-reports/exclusives/91489
  112. 112.0 112.1 Thompson MG, Burgess JL, Naleway AL, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. ePub: 29 March 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33793460 https://www.cdc.gov/mmwr/volumes/70/wr/mm7013e3.htm
  113. Laine C, Cotton D, Moyer DV COVID-19 Vaccine: Practical Clinical Considerations Ann Intern Med 2021. March 26 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33769829 https://www.acpjournals.org/doi/10.7326/M21-1260
  114. Goodman B Where Do COVID Vaccines Stand Against the Variants? Medscape - Mar 29, 2021. https://www.medscape.com/viewarticle/948335
  115. 115.0 115.1 Frellick M Vaccine Mismatch: What to Do After Dose 1 When Plans Change Medscape - Mar 25, 2021. https://www.medscape.com/viewarticle/948131
  116. 116.0 116.1 Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents Pfizer News Release. March 31, 2021 https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal
  117. 117.0 117.1 117.2 Pfizer News Release. April 1, 2021 Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious
  118. 118.0 118.1 National Institutes of Health (NIAID) NIH clinical trial evaluating Moderna COVID-19 variant vaccine begins Early-stage trial to evaluate safety and immunogenicity. News release. March 31, 2021 https://www.nih.gov/news-events/news-releases/nih-clinical-trial-evaluating-moderna-covid-19-variant-vaccine-begins
  119. 119.0 119.1 Shen X, Tang H, Pajon R et al Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351 N Engl J Med. April 7, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33826819 https://www.nejm.org/doi/full/10.1056/NEJMc2103740
  120. 120.0 120.1 120.2 120.3 Walker M Moderna's COVID Vax Produces Antibody Responses 6 Months Later. But neutralizing activity declined over time, and not equally among age groups. MedPage Today April 6, 2021 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/91954
    Doria-Rose N, Suthar MS, Makowski M et al Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med 2021. April 6 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33822494 https://www.nejm.org/doi/full/10.1056/NEJMc2103916
    Naaber P, Jurenson V, Adamson A et al Antibody response after COVID-19 mRNA vaccination in relation to age, sex, and side effects. MedRxiv. April 27, 2021 https://www.medrxiv.org/content/10.1101/2021.04.19.21255714v1.full
  121. 121.0 121.1 Greinacher A, Thiele T, Warkentin TE et al Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med 2021. April 9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33835769 https://www.nejm.org/doi/full/10.1056/NEJMoa2104840
    Schultz NH, Sorvoll IH, Michelsen AE et al Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med 2021. April 9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33835768 https://www.nejm.org/doi/full/10.1056/NEJMoa2104882
  122. 122.0 122.1 Weiland N, LaFraniere S, Zimmer C Johnson & Johnson Vaccine: Blood Clotting Cases Cause Calls for Pause in US. New York Times. 2021. April 13 https://www.msn.com/en-us/news/us/johnson-and-johnson-vaccine-blood-clotting-cases-cause-calls-for-pause-in-us/ar-BB1fB8wg
    Schuchat A, Marks P Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine. Media Statement. April 13, 2021 https://www.cdc.gov/media/releases/2021/s0413-JJ-vaccine.html
    Centers for Disease Control & Prevention (CDC) Cases of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Receipt of the Johnson & Johnson COVID-19 Vaccine. CDC Health Alert Network. April 13, 2021 https://emergency.cdc.gov/han/2021/han00442.asp
    McNamara D FDA, CDC Urge Pause of J&J COVID Vaccine. Medscape - Apr 13, 2021. https://www.medscape.com/viewarticle/949174
    Centers for Disease Control & Prevention (CDC) ACIP Meeting Information. April 14, 2021 https://www.cdc.gov/vaccines/acip/meetings/index.html
    Muir KL, Kallam A, Koepsell SA et al Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination N Engl J Med. 2021. April 14 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33852795 https://www.nejm.org/doi/full/10.1056/NEJMc2105869
  123. 123.0 123.1 Gray KJ, Bordt EA, Atyeo C et al COVID-19 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol. 2021. Mar 24;S0002-9378(21)00187-3 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33775692 PMCID: PMC7997025 Free PMC article https://www.ajog.org/article/S0002-9378(21)00187-3/pdf
  124. 124.0 124.1 Lubell M South African Variant May Evade Protection From Pfizer Vaccine, Israeli Study Says. Medscape. April 13, 2021 https://www.medscape.com/viewarticle/949111
    Kustin T, Harel N, Finkel U et al Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals. medRxiv. April 9, 2021 Not indexed in PubMed https://www.medrxiv.org/content/10.1101/2021.04.06.21254882v1
  125. 125.0 125.1 Walsh N New Side Effect From mRNA COVID Vaccines? Surprise finding in Israeli case series. MedPage Today April 15, 2021 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/92106
    Furer V, Zisman D, Kibari A et al Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Rheumatology 2021. April 12 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33848321 https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keab345/6225015
  126. 126.0 126.1 Blain H, Tuaillon E, Gamon L et al Spike Antibody Levels of Nursing Home Residents With or Without Prior COVID-19 3 Weeks After a Single BNT162b2 Vaccine Dose. JAMA. Published online April 15, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33856406 https://jamanetwork.com/journals/jama/fullarticle/2778926
  127. 127.0 127.1 Russell P Vaccines Carry Far Lower Risk for Rare Blood Clots Than COVID, Study Shows. Medscape - Apr 15, 2021 https://www.medscape.com/viewarticle/949366
  128. 128.0 128.1 Emary KRW, Golubchik T, Aley PK et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): An exploratory analysis of a randomised controlled trial. Lancet 2021 Apr 10; 397:1351. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33798499 PMCID: PMC8009612 Free PMC article https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00628-0/fulltext
  129. 129.0 129.1 Ebinger JE, Fert-Bober J, Printsev I et al Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021 Apr 1. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33795870
  130. 130.0 130.1 130.2 Scully M, Singh D, Lown R et al Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021. April 16. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33861525 https://www.nejm.org/doi/full/10.1056/NEJMoa2105385
    Cines DB, Bussel JB SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. N Engl J Med. 2021. April 16. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33861524 https://www.nejm.org/doi/full/10.1056/NEJMe2106315
    Rizk JG, Gupta A, Sardar P et al Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine- Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis. A Review. JAMA Cardiol. Published online August 10, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34374713 https://jamanetwork.com/journals/jamacardiology/fullarticle/2783051
  131. 131.0 131.1 131.2 Bankhead C Low COVID Vaccine Response in Patients With Blood Cancers. Data in chronic lymphocytic leukemia, myeloma add to evidence from other studies. https://www.medpagetoday.com/hematologyoncology/hematology/92170
    Herishanu Y et al Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33861303 https://ashpublications.org/blood/article/doi/10.1182/blood.2021011568/475742/Efficacy-of-the-BNT162b2-mRNA-COVID-19-Vaccine-in
    Terpos E et al Low neutralizing antibody responses against SARS-CoV-2 in elderly myeloma patients after the first BNT162b2 vaccine dose. Blood 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33861315 https://ashpublications.org/blood/article/doi/10.1182/blood.2021011904/475743/Low-Neutralizing-Antibody-Responses-Against-SARS
  132. 132.0 132.1 Chappell KJ, Mordant FL, Li Z et al Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infectious Diseases. 2021. April 19. PMID: https://www.ncbi.nlm.nih.gov/pubmed/3388720 https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00200-0/fulltext
    Watterson D, Wijesundara DK, Modhiran N et al Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2. Clin Transl Immunology. 2021 Apr 5;10(4):e1269. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33841880 Free PMC article.
  133. 133.0 133.1 Shimabukuro TT, Kim SY, Myers TR et al Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. N Engl J Med. 2021. April 21. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33882218 https://www.nejm.org/doi/full/10.1056/NEJMoa2104983
  134. 134.0 134.1 134.2 Hacisuleyman E, Hale C, Saito Y et al Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med. 2021. April 21 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33882219 https://www.nejm.org/doi/full/10.1056/NEJMoa2105000
    Lange B, Gerigk M, Tenenbaum T Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers. N Engl J Med 2021. Aug 18. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34407332 https://www.nejm.org/doi/full/10.1056/NEJMc2108076
  135. 135.0 135.1 135.2 Walker M ACIP Green-Lights J&J Vax for All Adults. Recommends warning label, but says benefits outweigh the risks in pandemic setting. MedPage Today April 23, 2021 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/92262
  136. 136.0 136.1 136.2 Hackethal V Why Clotting Happens When Platelets Are Low. A hematologist explains the counterintuitive concept of clots with low platelets. MedPage Today April 23, 2021 https://www.medpagetoday.com/special-reports/exclusives/92243
  137. 137.0 137.1 Renoud L, Khouri C, Revol B et al Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database. JAMA Intern Med. Published online April 27, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33904857 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2779389
  138. 138.0 138.1 138.2 138.3 138.4 Rapaport L Separate Elective Corticosteroid Injections From COVID-19 Vaccination by Two Weeks. Medscape. April 26, 2021 https://www.medscape.com/viewarticle/949911
    Lee H, Punt JA, Patel J et al Do Corticosteroid Injections for the Treatment of Pain Influence the Efficacy of Adenovirus Vector-Based COVID-19 Vaccines? Pain Med. 2021 Apr 11:pnab130 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33839780 https://academic.oup.com/painmedicine/advance-article/doi/10.1093/pm/pnab130/6220338
    Lee H, Punt JA, Miller DC et al Do Corticosteroid Injections for the Treatment of Pain Influence the Efficacy of mRNA COVID-19 Vaccines? Pain Med. 2021 Apr 20;22(4):994-1000. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33605425 Free PMC article.
  139. 139.0 139.1 Levine-Tiefenbrun M, Yelin I, Katz R et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med 2021 Mar 29; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33782619 https://www.nature.com/articles/s41591-021-01316-7
  140. 140.0 140.1 COVAXIN<TM> - India's First Indigenous COVID-19 Vaccine https://www.bharatbiotech.com/covaxin.html
  141. 141.0 141.1 See I, Su JR, Lale A et al US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. JAMA. Published online April 30, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33929487 https://jamanetwork.com/journals/jama/fullarticle/2779731
    Karron RA, Key NS, Sharfstein JM. Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine. JAMA. Published online April 30, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33929484 https://jamanetwork.com/journals/jama/fullarticle/2779732
  142. 142.0 142.1 American Medical Association (AMA) AMA Morning Report. May 3, 2021
  143. 143.0 143.1 Shinde V, Bhikha S, Hoosain Z et al Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med 2021. May 5 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33951374 https://www.nejm.org/doi/full/10.1056/NEJMoa2103055
  144. 144.0 144.1 144.2 Abu-Raddad LJ, Chemaitelly H, Butt AA Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med 2021. May 5 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33951357 https://www.nejm.org/doi/full/10.1056/NEJMc2104974
  145. 145.0 145.1 145.2 Syrek R Trending Clinical Topic: P.1 Coronavirus Variant. Medscape - Apr 30, 2021. https://reference.medscape.com/viewarticle/949943
  146. 146.0 146.1 Angel Y, Spitzer A, Henig O et al Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. JAMA. Published online May 6, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33956048 https://jamanetwork.com/journals/jama/fullarticle/2779853
    Tang L, Hijano DR, Gaur AH et al Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce. JAMA. Published online May 6, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33956050 https://jamanetwork.com/journals/jama/fullarticle/2779854
  147. 147.0 147.1 Liu Y, Liu J, Xia H et al BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. N Eng J Med. 2021. May 12. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33979486 https://www.nejm.org/doi/full/10.1056/NEJMc2106083
  148. 148.0 148.1 American Medical Association (AMA) AMA Morning Rounds. May 13, 2021
    Sun LH, Nirappil F. Biden hails coronavirus vaccine for 12- to 15-year-olds as 'one more giant step' in fight against the pandemic. Washington Post. May 12, 2021 https://www.washingtonpost.com/health/2021/05/12/pfizer-vaccine-adolescents-cdc-advisory-panel/
  149. 149.0 149.1 149.2 149.3 149.4 149.5 Hackethal V Nasal Vaccines for COVID-19? Some argue intranasal vaccines, still in early trials, may be better at blocking transmission. MedPage Today May 11, 2021 https://www.medpagetoday.com/special-reports/exclusives/92527
    McNamara D How Intranasal COVID Vaccines Could Be 'Holy Grail' of Vaccination Medscape - Jul 23, 2021. https://www.medscape.com/viewarticle/955309 -
  150. 150.0 150.1 150.2 Collier AY, McMahan K, Yu J et al Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. JAMA. Published online May 13, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33983379 https://jamanetwork.com/journals/jama/fullarticle/2780202
  151. 151.0 151.1 151.2 Reuters mRNA Vaccines Likely Effective Against India Variant. Medscape. May 14, 2021 https://www.medscape.com/viewarticle/951107
    Edara VV, Lai L, Sahoo MK et al Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv. May 10, 2021 https://www.biorxiv.org/content/10.1101/2021.05.09.443299v1
  152. 152.0 152.1 FDA in Brief. May 19, 2021 FDA In Brief: FDA Authorizes Longer Time for Refrigerator Storage of Thawed Pfizer-BioNTech COVID-19 Vaccine Prior to Dilution, Making Vaccine More Widely Available. https://www.fda.gov/news-events/press-announcements/fda-brief-fda-authorizes-longer-time-refrigerator-storage-thawed-pfizer-biontech-covid-19-vaccine
  153. 153.0 153.1 Ellis R COVID Vaccines Protect Against Top Variants - WHO Says. Medscape - May 21, 2021. https://www.medscape.com/viewarticle/951657
  154. 154.0 154.1 Formeister EJ, Chien W, Agrawal Y et al Preliminary Analysis of Association Between COVID-19 Vaccination and Sudden Hearing Loss Using US Centers for Disease Control and Prevention Vaccine Adverse Events Reporting System Data. JAMA Otolaryngol Head Neck Surg. 2021;147(7):674-676 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34014263 PMCID: PMC8138749 (available on 2022-05-20) https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2780288
  155. Perl SH, Uzan-Yulzari A, Klainer H et al SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women. JAMA. 2021;325(19):2013-2014 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33843975 PMCID: PMC8042567 (available on 2021-10-12) https://jamanetwork.com/journals/jama/fullarticle/2778766
  156. 156.0 156.1 Brooks M AHA Reassures Myocarditis Rare After COVID Vaccination, Benefits Overwhelm Risks. Medscape - May 24, 2021. https://www.medscape.com/viewarticle/951730
  157. 157.0 157.1 157.2 Cash-Goldwasser S, Frieden T. Op-Ed: The Jury Is Out on COVID Boosters. Scientific evidence, not vaccine makers, must drive vaccine decisions. MedPage Today. May 24, 2021 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/92761
  158. 158.0 158.1 158.2 American Medical Association (AMA) AMA Morning Rounds. May 26, 2021
    CDC COVID-19 Vaccine Breakthrough Case Investigations Team COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1 - April 30, 2021. MMWR Morb Mortal Wkly Rep. ePub: 25 May 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34043615 https://www.cdc.gov/mmwr/volumes/70/wr/mm7021e3.htm
  159. 159.0 159.1 Walsh N Methotrexate Impairs COVID Vax Response - Can extra vaccine doses or discontinuing drug benefit patients with immune-mediated diseases? MedPage Today May 25, 2021 https://www.medpagetoday.com/rheumatology/arthritis/92777
    Haberman RH, et al Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis 2021. May 25 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34035003 https://ard.bmj.com/content/early/2021/05/18/annrheumdis-2021-220597
  160. 160.0 160.1 Hughes S Large Vessel Stroke Linked to AstraZeneca COVID Vaccine. Medscape - May 25, 2021. https://www.medscape.com/viewarticle/951852
  161. 161.0 161.1 Al Kaabi N, Zhang Y, Xia S et al Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults. A Randomized Clinical Trial. JAMA. Published online May 26, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34037666 https://jamanetwork.com/journals/jama/fullarticle/2780562
  162. 162.0 162.1 162.2 Bassett M Cancer Patients Develop 'Adequate' Immune Response to COVID Vax. In a prospective study in Israel, 90% of cancer patients were seropositive for antibodies. MedPage Today May 28, 2021 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/92845
    Massarweh A, Eliakim-Raz N, Stemmer A et al Evaluation of seropositivity following BNT162B2 messenger RNA vaccination for SARS-COV-2 in patients undergoing treatment for cancer. JAMA Oncol 2021. May 28 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34047765 https://jamanetwork.com/journals/jamaoncology/fullarticle/2780584
    Sun L, Warner JL, Parikh RB. Immune responses to SARS-CoV-2 among patients with cancer: What can seropositivity tell us? JAMA Oncol 2021. May 28 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34047766 https://jamanetwork.com/journals/jamaoncology/fullarticle/2780585
  163. 163.0 163.1 163.2 Frenck RW Jr, Klein NP, Kitchin N et al Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021 May 27 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34043894 https://www.nejm.org/doi/full/10.1056/NEJMoa2107456
  164. 164.0 164.1 164.2 Torjesen I Covid-19: Pfizer-BioNTech vaccine is "likely" responsible for deaths of some elderly patients, Norwegian review finds. BMJ 2021;373:n1372 May 27 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34045236 https://www.bmj.com/content/373/bmj.n1372
  165. 165.0 165.1 165.2 165.3 165.4 Crist C Pfizer Vaccine Protects Less Against India Variant. Medscape - Jun 04, 2021. https://www.medscape.com/viewarticle/952503
    Wall EC, Wu M, Harvey R et al Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet 2021. June 3 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34090624 PMCID: PMC8175044 Free PMC article https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01290-3/fulltext
    Ellis R Delta Variant and COVID-19 Vaccines: What to Know. Medscape - Jun 10, 2021. https://www.medscape.com/viewarticle/952897
    Liu J, Liu Y, Xia H et al BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature 2021. June 10 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34111888 https://www.nature.com/articles/s41586-021-03693-y
  166. 166.0 166.1 Adin ME, Isufi E, Kulon M et al Association of COVID-19 mRNA Vaccine With Ipsilateral Axillary Lymph Node Reactivity on Imaging. JAMA Oncol. Published online June 10, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34110378 https://jamanetwork.com/journals/jamaoncology/fullarticle/2780591
  167. 167.0 167.1 167.2 Brooks M EMA Warns of New AZ Vaccine Side Effect. Medscape - Jun 11, 2021. https://www.medscape.com/viewarticle/952972
  168. 168.0 168.1 168.2 168.3 Bassett M Cancer Patients See High Seroconversion Rates After COVID Vax. Dampened responses seen in those with hematological malignancies, however. MedPage Today June 11, 2021 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/93054
    Thakkar A, Gonzales-Lugo JD, Goradia N et al Seroconversion rates following COVID-19 vaccination amongst patients with cancer. Cancer Cell. 2021. June 5 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34133951 https://www.sciencedirect.com/science/article/pii/S1535610821002853
  169. 169.0 169.1 American medical Association (AMA) AMA Morning News. June 14, 2021
  170. 170.0 170.1 170.2 170.3 Walker M Novavax Crows Over High COVID Vaccine Efficacy in Adults. Company reports efficacy even against variants of concern in phase III trial. MedPage Today June 14, 2021 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/93087
    Crist C Novavax Says COVID Vaccine Works Against Variants. Medscape - Jun 14, 2021. https://www.medscape.com/viewarticle/953057
    Heath PT, Galiza EP, Baxter DN et al Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med. 2021. June 30 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34192426 https://www.nejm.org/doi/full/10.1056/NEJMoa2107659
  171. 171.0 171.1 Walker M COVID and Flu Vaccines Play Nice Together Novavax study found comparable efficacy when vaccines co-administered. MedPage Today June 15, 2021 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/93121
  172. 172.0 172.1 Gupta K, O'Brien WJ, Bellino P et al Incidence of SARS-CoV-2 Infection in Health Care Workers After a Single Dose of mRNA-1273 Vaccine. JAMA Netw Open. 2021;4(6):e2116416. June 16 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34132795 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2781173
  173. 173.0 173.1 173.2 173.3 173.4 Fiore K Myocarditis and COVID Vaccines: Where Do We Stand? U.S. and E.U. regulators haven't confirmed causal links; investigations ongoing. MedPage Today June 10, 2021 https://www.medpagetoday.com/special-reports/exclusives/93040
    NBC News via Medscape More Than 300 Heart Inflammation Cases Reported After Vaccination, CDC Says Medscape - Jun 18, 2021. https://www.medscape.com/viewarticle/953416
    Montgomery J, Ryan M, Engler R et al Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol. Published online June 29, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34185045 https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601
    Kim HW, Jenista ER, Wendell DC et al Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol. Published online June 29, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34185046 https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602
    Shay DK, Shimabukuro TT, DeStefano F. Myocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines. JAMA Cardiol. Published online June 29, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34185047 https://jamanetwork.com/journals/jamacardiology/fullarticle/2781600
    Navar AM, McNally E, Yancy CW et al Temporal Associations Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis. The Vaccine Safety Surveillance System Is Working. JAMA Cardiol. Published online June 29, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34185044 https://jamanetwork.com/journals/jamacardiology/fullarticle/2781599
  174. 174.0 174.1 Gonzalez DC, Nassau DE, Khodamoradi K et al Sperm Parameters Before and After COVID-19 mRNA Vaccination. JAMA. Published online June 17, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34137808 https://jamanetwork.com/journals/jama/fullarticle/2781360
  175. 175.0 175.1 Dolgin E CureVac COVID vaccine let-down spotlights mRNA design challenges. Nature News. 2021. June 18. https://www.nature.com/articles/d41586-021-01661-0
  176. 176.0 176.1 Aronoff DM COVID-19 Booster Shots Can Wait. Millions at home and abroad still need baseline protection from first and second doses. MedPage Today. June 18, 2021 https://www.medpagetoday.com/clinical-challenges/asco-cll/93092
  177. 177.0 177.1 177.2 177.3 177.4 Shemer A, Pras E, Einan-Lifshitz A et al Association of COVID-19 Vaccination and Facial Nerve Palsy. A Case-Control Study. JAMA Otolaryngol Head Neck Surg. Published online June 24, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34165512 https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2781367
    Tamaki A, Cabrera CI, Li S et al Incidence of Bell Palsy in Patients With COVID-19. JAMA Otolaryngol Head Neck Surg. Published online June 24, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34165518 https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2781368
    Chang CWD Bell Palsy and COVID-19. Overcoming the Fear of "Known Unknowns" JAMA Otolaryngol Head Neck Surg. Published online June 24, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34165521 https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2781369
  178. 178.0 178.1 George J Unusual Variant of Guillain-Barre Syndrome Linked to COVID Vaccines. Experts call for relationship between adenovirus vector vaccines and GBS to be studied. MedPage Today June 22, 2021 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/93227
    Allen CM, Ramsamy S, Tarr AW et al Guillain-Barre syndrome variant occurring after SARS-CoV-2 vaccination. Ann Neurol 2021. June 10 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34114269 https://onlinelibrary.wiley.com/doi/10.1002/ana.26144
    Maramattom BV, Krishnan P, Paul R et al Guillain-Barre Syndrome following ChAdOx1-S/nCoV-19 Vaccine. Ann Neurol 2021. June 10 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34114256 https://onlinelibrary.wiley.com/doi/10.1002/ana.26143
  179. 179.0 179.1 179.2 Robinson LB, Fu X, Hashimoto D et al Incidence of Cutaneous Reactions After Messenger RNA COVID-19 Vaccines. JAMA Dermatol. Published online June 23, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34160555 https://jamanetwork.com/journals/jamadermatology/fullarticle/2781364
  180. 180.0 180.1 Reuters Staff Germinal Centers Persist in Lymph Nodes After mRNA Vaccines. Medscape. June 29, 2021 https://www.medscape.com/viewarticle/953900
    Turner JS, O'Halloran JA, Kalaidina E. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 2021. June 28 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34182569 https://www.nature.com/articles/s41586-021-03738-2
  181. 181.0 181.1 181.2 Han B, Song Y, Li C et al Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021. June 28. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34197764 PMCID: PMC8238449 Free PMC article https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00319-4/fulltext
  182. 182.0 182.1 182.2 Kavanagh MM, Gostin LO, Sunder M Sharing Technology and Vaccine Doses to Address Global Vaccine Inequity and End the COVID-19 Pandemic. JAMA. Published online July 1, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34196659 https://jamanetwork.com/journals/jama/fullarticle/2781756
  183. Chodick G, Tene L, Patalon T et al Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization. JAMA Netw Open. 2021;4(6):e2115985 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34097044 PMCID: PMC8185600 Free PMC article https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780700
  184. 184.0 184.1 184.2 Sullivan P Pfizer to seek FDA authorization for booster of COVID-19 vaccine. The Hill. 2021. July 8 https://thehill.com/policy/healthcare/562169-pfizer-to-seek-fda-authorization-for-booster-of-covid-19-vaccine
    HHS.gov. July 8, 2021 Joint CDC and FDA Statement on Vaccine Boosters. https://www.hhs.gov/about/news/2021/07/08/joint-cdc-and-fda-statement-vaccine-boosters.html
  185. 185.0 185.1 Nogrady B Mounting evidence suggests Sputnik COVID vaccine is safe and effective. Nature News 2021. July 6 https://www.nature.com/articles/d41586-021-01813-2
  186. 186.0 186.1 186.2 George J FDA To Warn About Post-COVID Vax Guillain-Barre syndrome. Cases seen in people who received Johnson & Johnson;s vaccine. MedPage Today July 12, 2021 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/93537
    American Medical Association (AMA) AMA Morning Rounds. July 13, 2021
    McGliney L, Sun LH FDA adds new warning on Johnson & Johnson vaccine related to rare autoimmune disorder. Washington Post. July 12, 2021 https://www.washingtonpost.com/health/2021/07/12/johnson-and-johnson-warning/
  187. 187.0 187.1 Dolgin E. Quarter-dose of Moderna COVID vaccine still rouses a big immune response. Nature News. July 9, 2021 https://www.nature.com/articles/d41586-021-01893-0
  188. 188.0 188.1 George J Two Shots, Two Paralyses After COVID Vaccine. First report of two contralateral Bell's palsy episodes in the same patient. MedPage Today July 19, 2021 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/93643
    Burrows A et al Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses. BMJ Case Rep 2021. Jul 19;14(7):e243829 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34281950
  189. 189.0 189.1 189.2 189.3 Tada T, Zhou H, Samanovic MI et al Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants. bioRxiv. 2021. July 19 Not indexed in PubMed https://www.biorxiv.org/content/10.1101/2021.07.19.452771v1
  190. 190.0 190.1 Benotmane I, Gautier G, Perrin P et al Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses. JAMA. Published online July 23, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34297036 https://jamanetwork.com/journals/jama/fullarticle/2782538
  191. 191.0 191.1 191.2 191.3 191.4 Butt AA, Omer SB, Yan P et al SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting. Ann Intern Med 2021. Jul 20 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34280332 Free article https://www.acpjournals.org/doi/10.7326/M21-1577
  192. Krantz MS, Kwah JH, Stone CA Jr et al Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose. JAMA Intern Med. Published online July 26, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/3430962 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2782348
  193. 193.0 193.1 Sanchez van Kammen M, Heldner MR, Brodard J et al Frequency of Thrombocytopenia and Platelet Factor 4/Heparin Antibodies in Patients With Cerebral Venous Sinus Thrombosis Prior to the COVID-19 Pandemic. JAMA. 2021;326(4):332-338 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34213527 https://jamanetwork.com/journals/jama/fullarticle/2781791
  194. 194.0 194.1 194.2 194.3 McNamara D Pfizer Vaccine Protection Wanes After 6 Months: Study. Medscape - Jul 28, 2021. https://www.medscape.com/viewarticle/955601
    Thomas SJ, Moreira ED Jr, Kitchin N et al Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. medRxiv. July 18, 2021 Not indexed in PubMed https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1
    Thomas SJ, Moreira ED Jr, Kitchin N et al Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021 Sept 15. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34525277 PMCID: PMC8461570 Free PMC article https://www.nejm.org/doi/10.1056/NEJMoa2110345
  195. 195.0 195.1 Merrill ED, Kashem SW, Amerson EH et al Association of Facial Pustular Neutrophilic Eruption With Messenger RNA-1273 SARS-CoV-2 Vaccine. JAMA Dermatol. Published online July 28, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34319363 https://jamanetwork.com/journals/jamadermatology/fullarticle/2782441
  196. 196.0 196.1 Bergwerk M, Gonen T, Lustig Y et al Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N Engl J Med. 2021 Jul 28. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34320281 https://www.nejm.org/doi/10.1056/NEJMoa2109072
  197. 197.0 197.1 Kneisel K Did Tdap Shot Delay Immunogenicity of COVID Vaccine? Serology tests were requested by healthcare worker who fell a day after her COVID vaccine. MedPage Today August 9, 2021 https://www.medpagetoday.com/casestudies/infectiousdisease/93963
    Chilimuri S et al BNT162b2 mRNA vaccine interference with co-administration of Tdap vaccine. Am J Case Rep 2021; 22: e933003. July 25 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34304240 PMCID: PMC8317582 Free PMC article https://www.amjcaserep.com/abstract/index/idArt/933003
  198. 198.0 198.1 198.2 Walker M Pfizer and Moderna Go Head to Head Against Delta Variant knocked down effectiveness of one vaccine more than another, preprint finds. MedPage Today August 10, 2021 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/93982
    Puranik A, Lenehan PJ, Silver E et al Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv August 9, 2021 https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v2
  199. 199.0 199.1 199.2 American Medical Association AMA Morning Rounds. August 12, 2021 https://www.bulletinhealthcare.com/portfolio/american-medical-association-ama-morning-rounds/
    Bernstein L, Shammas B CDC guidance now official: Pregnant people should get coronavirus vaccine. Washington Post. August 1`, 2021 https://www.washingtonpost.com/health/2021/08/11/pregnant-covid-vaccine/
  200. 200.0 200.1 Rossin EJ, Gaiha GD Researchers Find Potential Path to a Broadly Protective COVID-19 Vaccine Using T cells. Massachusetts General Hospital. 2021. July 19 https://advances.massgeneral.org/research-and-innovation/article-external.aspx
    Nathan A, Rossin EJ, Kaseke C et al Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. Cell. 2021. June 29 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34265281 Free PMC article. https://www.cell.com/cell/fulltext/S0092-8674%2821%2900797-2
  201. 201.0 201.1 Medpage Today, August 18, 2020 Covid-19 Response https://www.medpagetoday.com/infectiousdisease/covid19vaccine/94098
  202. 202.0 202.1 Gilbert PB, Montefiori DC, McDermott A et al Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. MedRxiv. August 15, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34401888 Free PMC article. https://www.medrxiv.org/content/10.1101/2021.08.09.21261290v4
  203. 203.0 203.1 203.2 Debes AK, Xiao S, Colantuoni E et al Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers. JAMA Intern Med. Published online August 16, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34398173 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2782821
  204. 204.0 204.1 Walker M FDA Approves Pfizer's COVID Vaccine. "Milestone" in pandemic, acting FDA commissioner says. https://www.medpagetoday.com/infectiousdisease/covid19vaccine/94167
    FDA News Release. August 23, 2019 FDA Approves First COVID-19 Vaccine. https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine
  205. 205.0 205.1 Reuters Israel finds COVID-19 vaccine booster significantly lowers infection risk. Reuters. August 23, 2019 https://www.reuters.com/world/middle-east/israel-finds-covid-19-vaccine-booster-significantly-lowers-infection-risk-2021-08-22/
  206. 206.0 206.1 Pradhan R Scientists Say Biden Jumped the Gun With Vaccine Booster Plan Kaiser Health News via Medscape. August 20, 2021 https://www.medscape.com/viewarticle/956978
  207. Fiore K Don't Use Pfizer's COVID Vax Off-Label in Kids, Experts Warn. For those under 12, dosing being studied is far lower, and data not yet available. MedPage Today August 23, 2021 https://www.medpagetoday.com/pediatrics/generalpediatrics/94172
  208. 208.0 208.1 Goldshtein I, Nevo D, Steinberg DM et al Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 https://onlinelibrary.wiley.com/doi/10.1111/tid.13705https://onlinelibrary.wiley.com/doi/10.1111/tid.13705 Infection in Pregnant Women. JAMA. 2021;326(8):728-735 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34251417 PMCID: PMC8276131 (available on 2022-01-12) https://jamanetwork.com/journals/jama/fullarticle/2782047
  209. 209.0 209.1 209.2 209.3 209.4 Zimmer C Second Dose of J. & J. Vaccine Gives Strong Boost, Company Reports. New York Times. August 24, 2021 (via Doximity) https://www.doximity.com/articles/d5769040-5949-4336-9d7c-638c22702d27
  210. 210.0 210.1 Crist C Heart Inflammation More Common After COVID Than After Vaccination. Medscape. August 26, 2921 https://www.medscape.com/viewarticle/957343
    Barda N, Dagan N, Ben-Shlomo Y et al Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med 2021. August 25. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34432976 https://www.nejm.org/doi/full/10.1056/NEJMoa2110475
  211. 211.0 211.1 211.2 Reuters Staff Antibodies Fade Faster After Vaccine vs Actual Infection. Medscape. August 24, 2021 https://www.medscape.com/viewarticle/957089
    Israel A, Shenhar Y, Green I et al Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection. medRxiv. August 22, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34462761 Free PMC article. https://www.medrxiv.org/content/10.1101/2021.08.19.21262111v1
  212. 212.0 212.1 212.2 Steensels D, Pierlet N, Penders J et al Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273. JAMA. Published online August 30, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34459863 https://jamanetwork.com/journals/jama/fullarticle/2783797
  213. 213.0 213.1 Crist C COVID-19 Vaccines Still Highly Effective Against Hospitalization, CDC Data Show. Medscape. August 31, 2021 https://www.medscape.com/viewarticle/957897
  214. 214.0 214.1 Hall VG et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med 2021 Aug 11; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34379917 PMCID: PMC8385563 Free PMC article https://www.nejm.org/doi/10.1056/NEJMc2111462
  215. 215.0 215.1 Tenforde MW et al. Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adults - United States, March-July 2021. MMWR Morb Mortal Wkly Rep 2021 Aug 27; 70:1156. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34437524 Free article https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e2.htm
    Aslam S et al. Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients. Transpl Infect Dis 2021 Jul 29; e13705 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34324256 https://onlinelibrary.wiley.com/doi/10.1111/tid.13705
  216. 216.0 216.1 Shapiro Ben David S, Potasman I, Rahamim-Cohen D Rate of Recurrent Guillain-Barre Syndrome After mRNA COVID-19 Vaccine BNT162b2. JAMA Neurol. Published online September 1, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34468703 https://jamanetwork.com/journals/jamaneurology/fullarticle/2783708
  217. 217.0 217.1 Wadman M Having SARS-CoV-2 once confers much greater immunity than a vaccine - but vaccination remains vital ScienceInsider. August 26, 2021 https://www.science.org/news/2021/08/having-sars-cov-2-once-confers-much-greater-immunity-vaccine-vaccination-remains-vital
  218. 218.0 218.1 McDade TW, Demonbreun AR, Sancilio A et al Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history. Sci Rep 2021. 11, 17325 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34321523 PMCID: PMC8319431 Free PMC article https://www.nature.com/articles/s41598-021-96879-3
  219. 219.0 219.1 219.2 219.3 Mallapaty S India's DNA COVID vaccine is a world first - more are coming. The ZyCoV-D vaccine heralds a wave of DNA vaccines for various diseases that are undergoing clinical trials around the world. Nature News. Sept 2, 2021 https://www.nature.com/articles/d41586-021-02385-x
    Abbasi J India's New COVID-19 DNA Vaccine for Adolescents and Adults Is a First. JAMA. 2021;326(14):1365. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34636874 https://jamanetwork.com/journals/jama/fullarticle/2784978
  220. 220.0 220.1 Klein NP, Lewis N, Goddard K et al Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021 Sep 3. Online ahead of print. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34477808 https://jamanetwork.com/journals/jama/fullarticle/2784015
    Blumenthal KG, Phadke NA, Bates DW Safety Surveillance of COVID-19 mRNA Vaccines Through the Vaccine Safety Datalink. JAMA. 2021 Sep 3. Online ahead of print. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34477809 https://jamanetwork.com/journals/jama/fullarticle/2784017
  221. Frowry F Two More Reports of Functional Neurological Disorder After COVID-19 Vaccine. Medscape. August 30, 2021 https://www.medscape.com/viewarticle/957479
    Kim DD, Kung CS, Perez DL Helping the Public Understand Adverse Events Associated With COVID-19 Vaccinations. Lessons Learned From Functional Neurological Disorder. JAMA Neurol. 2021;78(7):789-790. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33835153 https://jamanetwork.com/journals/jamaneurology/fullarticle/2778192
  222. 222.0 222.1 Teres D, Strosberg MA. Can Intranasal COVID Vaccines Help Stop the Spread? It's time for new approaches to fighting this virus. MedPage Today. September 5, 2021 https://www.medpagetoday.com/opinion/second-opinions/94366
    Oran DP, Topol ECoV-2 B.1.617.2 (Delta) Variant Predominance CoV-2 B.1.617.2 (Delta) Variant Predominance To Beat COVID, We May Need a Good Shot in the Nose. Scientific American. March 2, 2021 https://www.scientificamerican.com/article/to-beat-covid-we-may-need-a-good-shot-in-the-nose/
  223. 223.0 223.1 Keehner J, Horton LE, Binkin NJ et al Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce.2 B.1.617.2 (Delta) Variant Predominance 2 B.1.617.2 (Delta) Variant Predominance Nine States, JuneNine States, June N Engl J Med. 2021. Sept. 1 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34469645 https://www.nejm.org/doi/full/10.1056/NEJMc2112981
  224. 224.0 224.1 Wiesel BB, Keeling LE. Shoulder Injury Related to Vaccine Administration. J Am Acad Orthop Surg. 2021 Sep 1;29(17):732-739 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34185028
  225. 225.0 225.1 Chu L, McPhee R, Huang W et al A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine Volume 39, Issue 20, 12 May 2021, Pages 2791-2799 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33707061 PMCID: PMC7871769 Free PMC article https://www.sciencedirect.com/science/article/pii/S0264410X21001535
  226. 226.0 226.1 Mateus J, Dan JM, Zhang Z et al Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-existing crossreactive T cell memory. medRxiv 2021. July 5 https://www.medrxiv.org/content/10.1101/2021.06.30.21259787v1 Science 2021 Sep 14;eabj9853 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34519540
  227. 227.0 227.1 Shah ASV, Gribben C, Bishop J et al Effect of Vaccination on Transmission of SARS-CoV-2 N Engl J Med 2021. Sept 8 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34496200 https://www.nejm.org/doi/10.1056/NEJMc2106757
  228. Fiore K Myocarditis VAERS Analysis Sparks Social Media Uproar. Doctors worry misinterpretation will fuel misinformation campaigns. MedPage Today September 15, 2021 https://www.medpagetoday.com/special-reports/exclusives/94530
    Hoeg TB, Krug A, Stevenson J, Mandrola J SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis. medRxiv. 2021 Sept 8 https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1
  229. 229.0 229.1 Grannis SJ, Rowley EA, Ong TC, et al. Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19-Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance - Nine States, June-August 2021. MMWR Morb Mortal Wkly Rep. ePub: 10 September 2021 https://www.cdc.gov/mmwr/volumes/70/wr/mm7037e2.htm
  230. 230.0 230.1 CDC Study Says Moderna Vaccine More Effective Than Pfizer and J&J Medscape - Sep 20, 2021. https://www.medscape.com/viewarticle/959073
  231. 231.0 231.1 Makary M Take Another Look at the Spacing Between COVID Vaccine Doses. Growing body of research suggests robust immune response with extended dosing interval. MedPage Today September 1, 2021 https://www.medpagetoday.com/opinion/marty-makary/94315
    Ledford H Delaying a COVID vaccine's second dose boosts immune response. Nature News. May 13, 2021 https://www.nature.com/articles/d41586-021-01299-y
  232. 232.0 232.1 Kharbanda EO, Haapala J, DeSilva M et al. Spontaneous abortion following COVID-19 vaccination during pregnancy. JAMA 2021 Sep 8; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34495304 https://jamanetwork.com/journals/jama/fullarticle/2784193
    Zauche LH, Wallace B, Smoots AN et al. Receipt of mRNA Covid-19 vaccines and risk of spontaneous abortion. N Engl J Med 2021 Sep 8; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34496196 Free PMC article https://www.nejm.org/doi/10.1056/NEJMc2113891
  233. El Sahly HM, Baden LR, Essink B et al Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021. Sept 22. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34551225 https://www.nejm.org/doi/full/10.1056/NEJMoa2113017
  234. 234.0 234.1 234.2 Diaz GA, Parsons GT, Gering SK et al Myocarditis and Pericarditis After Vaccination for COVID-19. JAMA. 2021;326(12):1210-1212 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34347001 PMCID: PMC8340007 (available on 2022-02-04) https://jamanetwork.com/journals/jama/fullarticle/2782900?
  235. 235.0 235.1 Sanchez van Kammen N, Aguiar de Sousa D, Poli S et al Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. JAMA Neurol. Published online September 28, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34581763 https://jamanetwork.com/journals/jamaneurology/fullarticle/2784622
  236. 236.0 236.1 Barbhaiya M, Levine JM, Bykerk VP et al. Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City. Ann Rheum Dis 2021;80:1352 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34158370 https://ard.bmj.com/content/annrheumdis/80/10/1352.full.pdf
  237. Thompson MG, Stenehjem E, Grannis S et al. Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. N Engl J Med 2021 Sep 8; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34496194 PMCID: PMC8451184 Free PMC article https://www.nejm.org/doi/10.1056/NEJMoa2110362
  238. Pilishvili T, Gierke R, Fleming-Dutra KE et al. Effectiveness of mRNA Covid-19 vaccine among U.S. health care personnel. N Engl J Med 2021 Sep 22; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34551224 https://www.nejm.org/doi/10.1056/NEJMoa2106599
  239. Baden LR, El Sahly HM, Essink B et al. Covid-19 in the phase 3 trial of mRNA-1273 during the delta-variant surge. medRxiv 2021 Sep 22; [e-pub]. https://www.medrxiv.org/content/10.1101/2021.09.17.21263624v1
  240. 240.0 240.1 240.2 Rubin R COVID-19 Vaccine Nasal Spray. JAMA. 2021;326(12):1138 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34581751 https://jamanetwork.com/journals/jama/fullarticle/2784523
  241. 241.0 241.1 Locke T Having Flu and COVID Vaccines at Same Time Is Safe: ComFluCOV Study. Medscape. October 1, 2021. https://www.medscape.com/viewarticle/960081
    Lazarus R, Baos S, Cappel-Porter H et al The Safety and Immunogenicity of Concomitant Administration of COVID-19 Vaccines (ChAdOx1 or BNT162b2) with Seasonal Influenza Vaccines in Adults: A Phase IV, Multicentre Randomised Controlled Trial with Blinding (ComFluCOV). Lancet Preprint. 2021. September 30. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3931758
  242. 242.0 242.1 Simone A, Herald J, Chen A et al Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older. JAMA Intern Med. 2021. October 4. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34605853 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2784800
    Verma AK, Lavine KJ, Lin CY Myocarditis after Covid-19 mRNA Vaccination. N Engl J Med. 2021. Sept 30 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34407340 PMCID: PMC8385564 Free PMC article https://www.nejm.org/doi/full/10.1056/NEJMc2109975
  243. 243.0 243.1 Crist C Pfizer COVID Vaccine Antibodies May Disappear in 7 Months, Study Says. Medscape. October 4, 2021 https://www.medscape.com/viewarticle/960214
    Suthar MS, Arunachalam PS, Hu M et al Durability of immune responses to the BNT162b2 mRNA vaccine. bioRxiv. September 30, 2021 https://www.biorxiv.org/content/10.1101/2021.09.30.462488v1
    Levin EG, Lustig Y, Cohen C et al Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med. 2021. Oct 6 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34614326 https://www.nejm.org/doi/10.1056/NEJMoa2114583
    Chemaitelly H, Tang P, Hasan MR et al Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021. Oct 6 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34614327 https://www.nejm.org/doi/10.1056/NEJMoa2114114
  244. 244.0 244.1 John BV, Deng Y, Scheinberg A et al Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis. JAMA Intern Med. 2021;181(10):1306-1314. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34254978 PMCID: PMC8278308 (available on 2022-07-13) https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2782121
  245. 245.0 245.1 Tan CW, Chia WN, Young BE et al Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors. N Engl J Med. 2021. August 18. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34407341 PMCID: PMC8422514 Free PMC article https://www.nejm.org/doi/10.1056/NEJMoa2108453
  246. 246.0 246.1 246.2 Mallapaty S COVID vaccines cut the risk of transmitting Delta - but not for long. Nature 2021. Oct 5 https://www.nature.com/articles/d41586-021-02689-y
  247. 247.0 247.1 Woo EJ, Mba-Jonas A, Dimova RB et al Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Abbasi Presumptive Guillain-Barre Syndrome, February-July 2021. JAMA. Published online October 7, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34617967 https://jamanetwork.com/journals/jama/fullarticle/2785009
  248. 248.0 248.1 248.2 248.3 Walker M Study: Drug Use a Factor in COVID Breakthrough Infections. Cocaine, cannabis users at highest risk. MedPage Today October 6, 2021 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/94893
    Wang L, Wang QQ, Davis PB et al Increased risk for COVID-19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021. World Psychiatry 2021. October 5 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34612005 https://onlinelibrary.wiley.com/doi/10.1002/wps.20921
  249. 249.0 249.1 Goodman B FDA Neutral on Moderna Bid for COVID Booster Ahead of Decisive Meeting. Medscape. October 12, 2021 https://www.medscape.com/viewarticle/960750
  250. 250.0 250.1 Callaway E COVID super-immunity: one of the pandemic's great puzzles. Nature News. 2021. Oct 14 https://www.nature.com/articles/d41586-021-02795-x
  251. 251.0 251.1 251.2 Rubin R Trying to Block SARS-CoV-2 Transmission With Intranasal Vaccines. JAMA. Published online October 14, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34647956 https://jamanetwork.com/journals/jama/fullarticle/2785303
  252. Teres D, Stone DM, Strosberg MA. Can Intranasal Vaccines Stop Breakthrough COVID? Systematic vaccination is necessary but may not be sufficient for those at high risk. MedPage Today. October 23, 2021 https://www.medpagetoday.com/opinion/second-opinions/95212
  253. Putka S CDC Now Reports COVID Cases and Deaths by Vax Status. New tool also reveals numeric differences between vaccines. MedPage Today October 19, 2021. https://www.medpagetoday.com/special-reports/exclusives/95119
  254. 254.0 254.1 Crist C People Vaccinated Against COVID Less Likely to Die From Any Cause: Study. Medscape. October 25, 2021. https://www.medscape.com/viewarticle/961529
  255. 255.0 255.1 Goodman B FDA Panel Votes to Approve Pfizer's Vaccine for Children. Medscape. October 26, 2021 https://www.medscape.com/viewarticle/961645
  256. 256.0 256.1 George J Rare Neurologic Events More Common After COVID Infection Than After Vaccine. Study looks at outcomes for 32 million people in England. MedPage Today October 26, 2021 Goodman https://www.medpagetoday.com/neurology/generalneurology/95276
    Patone M, Handunnetthi L, Saatci D et al Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med 2021. October 25https://jamanetwork.com/journals/jama/fullarticle/2786039 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34697502 https://www.nature.com/articles/s41591-021-01556-7
  257. Waltz E COVID vaccine makers brace for a variant worse than Delta. Nature News. October 20, 2021 https://www.nature.com/articles/d41586-021-02854-3
  258. 258.0 258.1 Fox M FDA authorizes Pfizer's Covid-19 vaccine for children 5 to 11. CNN Health. October 29, 2921 https://www.cnn.com/2021/10/29/health/pfizer-vaccine-fda-eua-young-kids-bn/index.html
    Goodman B FDA Authorizes Pfizer's COVID-19 Vaccine for Children 5-11. Medscape. October 29, 2021 https://www.medscape.com/viewarticle/961894
    Walker M FDA Authorizes First COVID Vaccine for Younger Kids. Agency emphasizes immune response, safety data in children ages 5 to 11 years. MedPage Today October 29, 2021 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/95348
  259. 259.0 259.1 Bozio CH, Grannis SJ, Naleway AL, et al. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. ePub: 29 October 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34735425 https://www.cdc.gov/mmwr/volumes/70/wr/mm7044e1.htm
  260. 260.0 260.1 Tenforde MW, Self WH, Adams K et al Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA. Published online November 4, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34734975 https://jamanetwork.com/journals/jama/fullarticle/2786039
  261. 261.0 261.1 Crist C Unvaccinated People 20 Times More Likely to Die From COVID: Texas Study. Medscape. November 09, 2021 https://www.medscape.com/viewarticle/962606
  262. 262.0 262.1 262.2 Lazarus R, Baos S, Cappel-Porter H et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): A multicentre, randomised, controlled, phase 4 trial. Lancet 2021 Nov 11; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34774197 PMCID: PMC8585490 Free PMC article https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02329-1/fulltext
  263. 263.0 263.1 AMA Morning Rounds. December 17, 2021 CDC panel recommends use of Pfizer, Moderna COVID-19 vaccines over J&J shot due to blood clot risk. American Medical Association (AMA)
    Goodman B CDC Panel Backs mRNA COVID Vaccines Over J&J Due to Rare Clot Risk. Medscape. December 16, 2021 https://www.medscape.com/viewarticle/964998
  264. 264.0 264.1 Hsu L, Grune B, Buess M et al. COVID-19 breakthrough infections and transmission risk: Real-world data analyses from Germany's largest public health department (Cologne). Vaccines (Basel) 2021 Nov 2; 9:1267. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34835198 PMCID: PMC8624814 Free PMC article https://www.mdpi.com/2076-393X/9/11/1267
  265. 265.0 265.1 Firth S OK'd; Booster Wanes at 10 Weeks? A daily roundup of news on COVID-19 and the rest of medicine MedPage Today December 27, 2021 https://www.medpagetoday.com/infectiousdisease/covid19/96376
  266. Johnston MS, Galan A, Watsky KL et al Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine. A Case Series. JAMA Dermatol. 2021;157(6):716-720 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33978670 PMCID: PMC8117061 (available on 2022-05-12) https://jamanetwork.com/journals/jamadermatology/fullarticle/2779643
  267. 267.0 267.1 267.2 Beatty AL, Peyser ND, Butcher XE et al Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination. JAMA Netw Open. 2021;4(12):e2140364 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34935921 Free article https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2787361
  268. 268.0 268.1 Jabagi MJ, Botton J, Bertrand M et al Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older. JAMA. 2022;327(1):80-82 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34807248 PMCID: PMC8609457 (available on 2022-05-22) https://jamanetwork.com/journals/jama/fullarticle/2786667
  269. 269.0 269.1 Hotez PJ, Bottazzi ME A COVID Vaccine for All. Scientific American. December 30, 2021 https://www.scientificamerican.com/article/a-covid-vaccine-for-all/
  270. 270.0 270.1 Wang L, Davis PB, Kaelber DC et al Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period. JAMA. Published online January 20, 2022 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35050314 https://jamanetwork.com/journals/jama/fullarticle/2788408
  271. 271.0 271.1 Federman J Israel study: 4th vaccine shows limited results with omicron. Associated Press (AP). Jan 17, 2022 https://apnews.com/article/coronavirus-pandemic-health-middle-east-israel-5da0bbef16209e9c55e48af40248af11
  272. 272.0 272.1 Accorsi EK, Britton A, Fleming-Dutra KE et al Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. Published online January 21, 2022. PMID: https://www.ncbi.nlm.nih.gov/pubmed/3506099 https://jamanetwork.com/journals/jama/fullarticle/2788485
  273. 273.0 273.1 Oster ME, Shay DK, Su JR et al Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA. 2022;327(4):331-340. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35076665 https://jamanetwork.com/journals/jama/fullarticle/2788346
  274. 274.0 274.1 Danza P, Koo TH, Haddix M et al SARS-CoV-2 Infection and Hospitalization Among Adults Aged >= 18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022. MMWR Morb Mortal Wkly Rep. ePub: 1 February 2022 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35113851 https://www.cdc.gov/mmwr/volumes/71/wr/mm7105e1.htm
  275. 275.0 275.1 275.2 275.3 Haas JW, Bender FL, Ballou S et al Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials. A Systematic Review and Meta-analysis. JAMA Netw Open. 2022;5(1):e2143955 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35040967 PMCID: PMC8767431 Free PMC article https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788172
  276. 276.0 276.1 276.2 276.3 Reuters Staff Data Shows Sanofi-GSK COVID Vax Highly Effective, Companies to Seek FDA OK. Medscape. Feb 23, 2022 https://www.medscape.com/viewarticle/968987
  277. 277.0 277.1 Formeister EJ, Wu MJ, Chari DA et al Assessment of Sudden Sensorineural Hearing Loss After COVID-19 Vaccination. JAMA Otolaryngol Head Neck Surg. Published online February 24, 2022 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35201274 https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2789496
  278. 278.0 278.1 278.2 Dorabawila V, Hoefer D, Bauer UE et al Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant. medRxiv 2022. Feb 28 https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1
  279. 279.0 279.1 Hall V, Foulkes S, Insalata F et al. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N Engl J Med 2022 Feb 16; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/35172051 https://www.nejm.org/doi/10.1056/NEJMoa2118691
    Hammerman A, Sergienko R, Friger M et al. Effectiveness of the BNT162b2 vaccine after recovery from Covid-19. N Engl J Med 2022 Feb 16; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/35172072 https://www.nejm.org/doi/10.1056/NEJMoa2119497
  280. 280.0 280.1 Wright BJ, Tideman S, Diaz GA et al Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study. Lancet Respiratoory Medicine. 2022. Feb 25. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35227415 PMCID: PMC8881000 https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00042-X/fulltext
  281. 281.0 281.1 Magnus MC et al. Association of SARS-CoV-2 vaccination during pregnancy with pregnancy outcomes. JAMA 2022 Mar 24; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35323851 https://jamanetwork.com/journals/jama/fullarticle/2790608
    Fell DB et al. Association of COVID-19 vaccination in pregnancy with adverse peripartum outcomes. JAMA 2022 Mar 24; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/35323842 https://jamanetwork.com/journals/jama/fullarticle/2790607
  282. 282.0 282.1 282.2 Friedensohn L et al. Myocarditis following a third BNT162b2 vaccination dose in military recruits in Israel. JAMA 2022 Mar 17; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35297962 PMCID: PMC8931670 (available on 2022-09-17) https://jamanetwork.com/journals/jama/fullarticle/2790421
  283. 283.0 283.1 Yanir Y, Doweck I, Shibli R et al Association Between the BNT162b2 Messenger RNA COVID-19 Vaccine and the Risk of Sudden Sensorineural Hearing Loss. JAMA Otolaryngol Head Neck Surg. 2022;148(4):299-306. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35201275 PMCID: PMC8874902 (available on 2023-02-24) https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2789497
    Formeister EJ, Wu MJ, Chari DA et al. Assessment of Sudden Sensorineural Hearing Loss After COVID-19 Vaccination. JAMA Otolaryngol Head Neck Surg. 2022;148(4):307-31 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35201274 PMCID: PMC8874871 (available on 2023-02-24) https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2789496
    Ulrich AK, Sundaram ME, Osterholm MT Rare Sudden Sensorineural Hearing Loss Potentially Associated With COVID-19 Vaccination Does Not Outweigh the Benefit of COVID-19 Vaccines. JAMA Otolaryngol Head Neck Surg. 2022;148(4):315-316 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35201285 https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2789500
  284. 284.0 284.1 284.2 284.3 284.4 Ling RR et al. Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: A systematic review and meta-analysis. Lancet Respir Med 2022 Apr 11; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/35421376 PMCID: PMC9000914 Free PMC article https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00059-5/fulltext
  285. 285.0 285.1 Walker M FDA Severely Limits Use of J&J COVID Shot. Decision comes more than a year after "pause" over rare clotting events. MedPage Today May 5, 2022 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/98575
  286. 286.0 286.1 Kildegaard H et al. Risk of appendicitis after mRNA COVID-19 vaccination in a Danish population. JAMA Intern Med 2022 Apr 25; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/35467699 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2791667
  287. 287.0 287.1 Stulpin C FDA authorizes Novavax's COVID-19 vaccine, expanding options in US. Helio Infectious Disease. July 14, 2022 https://www.healio.com/news/infectious-disease/20220714/fda-authorizes-novavaxs-covid19-vaccine-expanding-options-in-us
  288. 288.0 288.1 288.2 288.3 Walz E How nasal-spray vaccines could change the pandemic Nature. 2022. September 6 https://www.nature.com/articles/d41586-022-02824-3
    Walz E China and India approve nasal COVID vaccines - are they a game changer? Nature. 2022. September 7 https://www.nature.com/articles/d41586-022-02851-0
  289. 289.0 289.1 Hermann EA, Lee B, MD2; Balte PP et al Association of Symptoms After COVID-19 Vaccination With Anti-SARS-CoV-2 Antibody Response in the Framingham Heart Study. JAMA Netw Open. 2022;5(10):e2237908 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36269359 Free article https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797552
  290. 290.0 290.1 Slomski A Intranasal COVID-19 Vaccine Disappointing in First-in-Human Trial. JAMA. 2022;328(20):2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36413233 https://jamanetwork.com/journals/jama/fullarticle/2798745
    Madhavan M, Ritchie AJ, Aboagye J et al Tolerability and immunogenicity of an intranasally-administered adenovirus- vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial. EBioMedicine. 2022 Nov;85:104298. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36229342 PMCID: PMC9550199 Clinical Trial.
  291. 291.0 291.1 Mao T et al. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science 2022 Nov 25; 378:eabo2523. https://www.science.org/doi/10.1126/science.abo2523
  292. 292.0 292.1 Kwan AC, Ebinger JE, Wei J et al Apparent risks of postural orthostatic tachycardia syndrome diagnoses after COVID-19 vaccination and SARS-Cov-2 Infection. Nat Cardiovasc Res 2022. Dec 12 Not indexed in PubMed https://www.nature.com/articles/s44161-022-00177-8
  293. 293.0 293.1 Nieminen TA, Kivekas I, Artama M et al Sudden Hearing Loss Following Vaccination Against COVID-19. JAMA Otolaryngol Head Neck Surg. Published online December 15, 2022. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36520464 https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2799360
  294. 294.0 294.1 Yasuhara J et al. Myopericarditis after COVID-19 mRNA vaccination among adolescents and young adults: A systematic review and meta-analysis. JAMA Pediatr 2022 Dec 5; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36469338 https://jamanetwork.com/journals/jamapediatrics/fullarticle/2798866
  295. 295.0 295.1 Tu W, Zhang P, Roberts A et al SARS-CoV-2 Infection, Hospitalization, and Death in Vaccinated and Infected Individuals by Age Groups in Indiana, 2021-2022. Am J Public Health. 2022, Dec 14. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36516380 https://ajph.aphapublications.org/doi/10.2105/AJPH.2022.307112
  296. 296.0 296.1 296.2 Sinha S, Konetzka RT Association of COVID-19 Vaccination Rates of Staff and COVID-19 Illness and Death Among Residents and Staff in US Nursing Homes. JAMA Netw Open. 2022;5(12):e2249002. Dec 29. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36580329 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799964
  297. 297.0 297.1 Yoshikawa T et al. Axillary lymphadenopathy after Pfizer-BioNTech and Moderna COVID-19 vaccination: MRI evaluation. Radiology 2023 Jan; 306:270. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36098641 PMCID: PMC9490792 Free PMC article https://pubs.rsna.org/doi/10.1148/radiol.220814
  298. 298.0 298.1 Brooks M More Data Back Guillain-Barre Risk With Janssen COVID Shot. Medscape. Feb 3, 2023 https://www.medscape.com/viewarticle/987838
  299. 299.0 299.1 Wu N, Joyal-Desmarais K, Ribeiro PAB et al Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. Lancet Respir Med. 2023. Feb 10. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36780914 PMCID: PMC9917454 Free PMC article https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00015-2/fulltext
  300. 300.0 300.1 George J Bell's Palsy Occurred More Frequently With COVID Vaccines. But SARS-CoV-2 infection tripled the risk over vaccination MedPage Today April 27, 2023 https://www.medpagetoday.com/neurology/generalneurology/104234
    Rafati A, Pasebani Y, Jameie M et al Association of SARS-CoV-2 Vaccination or Infection With Bell Palsy. A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. Published online April 27, 2023. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37103913 https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2804297
  301. 301.0 301.1 The White House The Biden-Harris Administration Will End COVID-19 Vaccination Requirements for Federal Employees, Contractors, International Travelers, Head Start Educators, and CMS-Certified Facilities. https://www.whitehouse.gov/briefing-room/statements-releases/2023/05/01/the-biden-administration-will-end-covid-19-vaccination-requirements-for-federal-employees-contractors-international-travelers-head-start-educators-and-cms-certified-facilities/
  302. 302.0 302.1 Harris E BCG Vaccine Not Effective Against COVID-19. JAMA. Published online May 3, 2023. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37133901 https://jamanetwork.com/journals/jama/fullarticle/2804705
  303. 303.0 303.1 303.2 Wallace J, Goldsmith-Pinkham P, Schwartz JI Excess Death Rates for Republican and Democratic Registered Voters in Florida and Ohio During the COVID-19 Pandemic. JAMA Intern Med. Published online July 24, 2023. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37486680 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2807617
  304. 304.0 304.1 George J Rare Syndrome After COVID Vaccines Described. "Long vax" events often include neurologic symptoms. MedPage Today December 1, 2023 https://www.medpagetoday.com/neurology/generalneurology/107644
    Krumholz HM, Wu Y, Sawano M et al Post-Vaccination Syndrome: A Descriptive Analysis of Reported Symptoms and Patient Experiences After Covid-19 Immunization. medRxiv 2023. Nov 10 https://www.medrxiv.org/content/10.1101/2023.11.09.23298266v1
  305. 305.0 305.1 Rubin R Up the Nose and Down the Windpipe May Be the Path to New and Improved COVID-19 Vaccines. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38055302 JAMA. Published online December 6, 2023. https://jamanetwork.com/journals/jama/fullarticle/2812830
  306. 306.0 306.1 Norman M, Magnus MC, Soderling J et al Neonatal Outcomes After COVID-19 Vaccination in Pregnancy. JAMA. 2024 Feb 6;331(5):396-407. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38319332 PMCID: PMC10848052 (available on 2024-08-06) https://jamanetwork.com/journals/jama/fullarticle/2814537
  307. 307.0 307.1 307.2 Mercade-Besora1 N, Li X, Kolde R et al The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications. Heart. 2024. Mar 12:heartjnl-2023-323483 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38471729 Free article https://heart.bmj.com/content/early/2024/01/24/heartjnl-2023-323483
  308. 308.0 308.1 Lou N Only One Harm From mRNA COVID Vaccines, Report Determines. Independent reviewers reject causal links to infertility, myocardial infarction, stroke. MedPage Today April 16, 2024 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/109700
  309. 309.0 309.1 Hu M, Shoaibi A, Feng Y et al Safety of Ancestral Monovalent BNT162b2, mRNA-1273, and NVX-CoV2373 COVID-19 Vaccines in US Children Aged 6 Months to 17 Years. JAMA Netw Open. 2024 Apr 1;7(4):e248192. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38656578
  310. 310.0 310.1 Rafati A et al Association of New-Onset Seizures With SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. JAMA Neurol. 2024 Apr 29:e240967. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38683573 PMCID: PMC11059047 (available on 2025-04-29)
  311. 311.0 311.1 311.2 311.3 311.4 Mao T, Kim J, Pena-Hernandez MA et al. Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract. Proc Natl Acad Sci U S A 2024 Apr 30; 121:e2319566121. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38648490 PMCID: PMC11067057 Free PMC article https://www.pnas.org/doi/10.1073/pnas.2319566121
  312. 312.0 312.1 National Institutes of Health, News Release. July 1, 2024 NIH-sponsored trial of nasal COVID-19 vaccine opens. Candidate vaccine could provide enhanced breadth of protection against emerging SARS-CoV-2 variants. https://www.nih.gov/news-events/news-releases/nih-sponsored-trial-nasal-covid-19-vaccine-opens
  313. Yale Health COVID-19 Vaccine Side Effects. https://yalehealth.yale.edu/yale-covid-19-vaccine-program/covid-19-vaccine-side-effects
  314. FACT SHEET FOR RECIPIENTS AND CAREGIVERS EMERGENCY USE AUTHORIZATION (EUA) OF THE MODERNA COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19) IN INDIVIDUALS 18 YEARS OF AGE AND OLDER. https://www.fda.gov/media/144638/download

Patient information

COVID-19 vaccine patient information